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     Reactive oxygen species are naturally generated within the human body and they are known to 
modulate signaling pathway and mediate other physiological activities. However, excessive 
generation of ROS and the inability of body defense system in detoxifying them results in the so 
called “oxidative stress”. Methionine has powerful antioxidant properties due to the presence of 
electronegative sulfur in its structure. Therefore, Met is readily oxidized, and methionine sulfoxide 
has been linked to several pathological conditions.  
      The urinary proteome is an attractive candidate for the discovery of biomarkers to diagnose 
and classify health conditions because of the non-invasive collection procedure. However, 
protocols developed for the analysis of the urinary proteome have limitations both in identification 
of proteins and eliminating false positives.  
      Urine samples were collected from smoker and non-smokers participants. Proteins were 
concentrated and concentrates then were subjected to separation via SDS-PAGE gel 
electrophoresis technique. Gel was cut out into five sections including the band representing intact 
HSA. Gel sections then were digested with trypsin. Total proteins and levels of methionine 
sulfoxide in the resulting peptides were assessed by mass spectrometry. Data analysis was 
performed using Scaffold and Skyline software packages.  
     Correspondence with predicted retention times, MS/MS sequence information, and a minimum 
of two tryptic peptides were required to reduce false positives. Proteins were matched to 1023 
UniProtKB identification numbers, 467 of which have not been previously reported in the human 
urinary proteome. Analysis of methionine sulfoxide proteome revealed 392 peptides mapped to 
198 proteins that were detected with a significant fold change in smokers. Regions of gels with 
proteins of lower mass showed significant higher levels of oxidation in smokers compared to 
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     The complete set of proteins and peptides within a particular body compartment is known as 
proteome. Proteomes include a wide spectrum ranging from proteins with high molecular masses 
to short polypeptide chains, proteins that are very abundant to extremely rare, and a wide variety 
of pre- and post-translational modifications. In contrast to genomes, which are relatively stable, 
proteomes are highly affected by factors including gene expression and protein secretion and 
turnover. Advances in protein detection and identification enables detecting even low abundance 
proteins or protein variants generated in response to certain health conditions or environmental 
factors.  
      Due to the inherent complexity of proteomes, samples are usually separated in some fashion 
prior to protein identification. The SDS-PAGE developed by Laemmli and the two-dimensional 
gel electrophoresis conducted by O’Farrell in mid 1970s were the earliest studies of what is known 
as proteomics today (1,2). The technique separates proteins based on their molecular masses. 
However, the challenge of protein identification in 2DE remained until Burnette described Western 
blot assay using antibodies (3). Such techniques have been used successfully for decades now. 
However, advancements in protein identification using mass spectrometry was a revolution in 
studying a wide array of proteins with greater accuracy. Today, experimental procedures rely on 
gel electrophoresis and/or liquid chromatography followed by mass spectrometry for 
identification. Moreover, LC can be easily coupled to almost all MS instruments (4-6). Identifying 
proteins using these two separation techniques often involves enzymatic digestion (7,8) of 
polypeptides at some stage to produce fragments that can be easily detected and identified by MS. 
Usually, the techniques uses at least two of the produced fragments to search in a protein database 
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for identification purposes. A key advantage of using MS techniques is that the peptide 
identification can be confirmed by MS/MS sequencing. However, 1DE technique has limitations 
such as low reproducibility and the significant long time required for the analysis. Liquid 
chromatography (LC) on the other hand, is a robust tool used in fractionation and separating 
complex biological samples.  
     As these techniques have improved, it is not surprising that proteomics has gained a 
considerable amount of attention over last few decades. Body fluids are attractive targets for 
clinical proteomics. Urinary proteomics has become a popular topic in clinical biomarker 
discovery. The simple and noninvasive nature of urine sampling provides large quantities of 
material Urine contains around 150 mg of protein in each 24 hour period (9).. It offers the potential 
for significant insights into normal and pathological conditions due to the wide range of its 
proteome profile. Urine directly reflects the condition of the urinary system, but also contains 
considerable amounts of plasma proteins and proteins from a wide range of cell types throughout 
the body (10). Thus, pathological and physiological changes can be detected in urine samples (11-
13). By means of comparative proteomics, many urinary proteins such as albumin, cystatin C, α-
1and β-2 microglobulin (14), have been identified as potential biomarkers reflecting different 
illnesses including glomerular dysfunction, bladder cancer, renal cell carcinoma, renal failure, 
diabetic nephropathy, acute kidney injury, and non-renal diseases including cardiovascular 
diseases (15,16) and atherosclerosis (17). One of the first studies that sought to more fully describe 
the urinary proteome using LC-MS was published by Spahr et al. (6,18). They pooled urine 
samples and the analysis resulted in identifying 124 proteins. Although the study did not attempt 
to discover any biomarkers, it paved the road toward further urine proteome examinations. Pang 
et al. (19) attempted to discover biomarkers specific for inflammation in urine samples of healthy 
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individuals. Later, scientists tried to study urine proteome more in depth. Thonboonkerd et al (20) 
defined the first human normal urinary proteome in 2002. They identified 47 unique proteins using 
2DE electrophoresis followed by matrix-assisted laser desorption ionization-time-of-flight 
(MALDI-TOF) mass spectrometry. Further expansion of human urinary proteome was reported 
by studies conducted later by Pieper et al. in 2004 (21), Sun et al (13), and Castagna et al. (22) in 
2005. These studies collectively identified less than 1,000 proteins. In the following years, studies 
continued mining urinary proteome and, as will be discussed in a subsequent chapter, the current 
urine proteome map encompass over 11,000 proteins.  
     Beyond identifying and quantifying proteins, another area of biomarker discovery using MS 
approaches is identification of posttranslational modifications (PTMs). The number of proteins in 
an organism exceeds the DNA coding capacity in response to the RNA metabolism and alternative 
splicing, also due  to the various covalent  posttranslational modifications (PTMs) occur at 
different sites (23). Many PTMs of proteins are intentional, specific, and vital for cellular survival. 
Examples would include proteolytic maturation, glycosylation, and phosphorylation events. 
Others may be more random in nature and possibly deleterious to the organism. Examples include 
proteolysis by pathogens, damage from ultraviolet light, Amadori modification of proteins by 
glucose in diabetes, and oxidation. PTMs can be observed in many pre-MS separations, since 
modification often changes mass or charge of the proteins or fragments being analyzed.  
     The use of or MS/MS approaches is vital if one to determine the precise location and nature of 
PTMs in the proteome. The first MS instrument is employed as a mass filter of the so called “parent 
ions” and the following MS step serves in analyzing products of fragmentation “daughter ions” 
induced via collision with other molecules in a process called collision-induced fragmentation 
(24). Even with MS/MS techniques to pinpoint the location of PTMs, their analysis can be 
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potentially difficult due to several factors including low abundance of the modified peptide, low 
stability of the modification, and the degree to which the modification itself impacts ionization 
efficiency. Samples handled for proteomic studies are typically treated with SDS, thus, extraction 
of proteins with PTMs could be different from unmodified proteins (25). While the location of 
some modifications can be determined via MS/MS, this requires the PTM to withstand different 
energetics used in MS and MS/MS analysis. Additionally, the shift in the mass due to the 
modification should not shift the mass of the peptide beyond the mass range being detected by 
MS/MS (~800-2500Da) (26). 
     The PTM of particular interest here is protein oxidation, which is of interest in different 
disciplines including for example, in studies of aging and age-related diseases, such as Alzheimer’s 
disease; in the field of therapeutic proteins; food-storage and in industrial biotechnology (27). The 
concept of oxidative stress was first introduced to redox biology by Helmut Sies in 1985 (28). 
Reactive oxygen species (ROS) are inevitable consequences of aerobic metabolism. Various 
cellular processes and enzymes are capable of generating oxidative PTMs. Later, oxidation of 
macromolecules in response to ROS was linked to a variety of pathologies. ROS leading to 
oxidative stress include free radicals such as superoxide (O.2-), hydroxyl (OH-), peroxy (RO2), 
alcoxyl (RO-), hydroperoxyl (HO.2), and non-radical species such as hydrogen peroxide (H2O2), 
hydrochlorous acid (HOCl), ozone (O3), singlet oxygen (1O2), and peroxinitrite (ONOO-) (29,30). 
Reuter et al. reviewed the link between oxidative stress, inflammation and cancer (31). They 
pointed that oxidative stress can activate transcriptional factor responsible for expression of over 
500 genes including those for cytokines and chemokines. They concluded that the three elements 
(oxidative stress, inflammation and cancer)  are closely related (31). The main source of 
endogenous ROS can be summarized as the addition of an electron to molecular oxygen to form 
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superoxide anion, which is mediated by NADPH that occurs in mitochondria (32). In addition, 
upon phagocytosis, macrophages evolve a bactericidal mechanism through the formation of 
oxidative burst. Superoxide is converted into hydrogen peroxide through the action of superoxide 
dismutase enzymes and the product can easily diffuse across the plasma membrane. Hydrogen 
peroxide then can breakdown to OH- in the presence of transition metals in Haber-Weiss and 
Fenton reactions (33,34). Hydroxyl radical is the most reactive among ROS and it can impair the 
function and damage proteins, lipids and nucleic acids (35).  
     Of course, the body is naturally able in some degree to detoxify generated oxygen species by 
producing antioxidants capable of capturing ROS. Imbalance between the formation and 
detoxification of ROS can result in oxidative stress and non-enzymatic modification of 
biomolecules (36). Oxidative damage to proteins can virtually affect all amino acids. However, 
methionine and cysteine residues react more readily due to the presence of sulfur atoms in their 
structures  (37-39). It has been proposed that these amino acids are among the main ROS 
scavengers and thus they protect proteins and other macromolecules from deleterious effects of 
oxidative damage (40).  
     The major product of oxidation of methionine is methionine sulfoxide and this PTM is the main 
focus of this dissertation. Methionine sulfoxide adducts are of great interest in that they can be 
reversed back to methionine via the action of methionine sulfoxide reductases. Further oxidation 
of methionine can lead to the formation of irreversible methionine sulfone (41).  
     Not all methionines are equally susceptible to oxidation.  Most methionine residues are 
localized in the hydrophobic core of proteins due their hydrophobicity and they mainly interact 
with lipid bilayer in the membrane proteins, therefore, many are fairly protected from oxidation 
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by polar oxidants. However, surface exposed methionine amino acids are susceptible to oxidation 
(42-46). But even on the surface, the rate of formation of methionine sulfoxide is dependent on the 
amino acids found in vicinity of Met. Ghesquiere et al. found that Met are more susceptible to 
oxidation when surrounded by acidic amino acids than basic ones (41).  
     The consequences of oxidative modification of proteins in general and methionine sulfoxide in 
particular can undergo biological degradation or tend to form larger aggregates due to increased 
surface hydrophobicity (47). In a review article, Stadtman et al., relying on a study conducted 
using E coli glutamine synthetase, stated that oxidation of methionine residues leads to 
conformational changes. The enzyme has ten surface-exposed Met residues. The study observed 
no detectable changes in surface hydrophobicity when seven of the residues were oxidized, but 
with further oxidation of two additional Met residues, a sharp increase in surface hydrophobicity 
was observed suggesting a conformational change led to expose buried residues to the outer 
surface, as result of  the change, proteolytic degradation via 20S proteasome was detected (48). 
Fujino et al. investigated cleavage sites of bovine serum albumin treated with H2O2. Computer 
model of BSA revealed that the products of cleavage induced by oxidized protein hydrolase are 
located in the internal core of the protein, and the oxidation influenced the structure in a way 
hydrophobic Met residues became accessible by the proteolytic enzyme. They replaced Met and 
tryptophan residues found in the hydrolysis products with their oxidized forms. Later, they found 
the fragments became more exposed to the solvent than un-oxidized BSA (49). Furtunatelly, 
oxidation of methionine is reversible via the action of methionine sulfoxide reductases (MsrA and 
MsrB). Several studies have examined the physiological importance of Msr enzymes in 
prokaryotes and eukaryotes. Gebendorfer et al.  noticed increased sensitivity and reduced viability 
of  mutant E. coli lacking the gene producing MsrA (50). Pennington et al. described an alternative 
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pathway in which Nrf2 transcription factor (binds to the antioxidant response element region of 
the DNA) initiates the transcription of genes responsible in the production of antioxidant enzymes 
under non-stressed conditions in mice with MsrA knockout (51). 
     While many research teams have sought to reveal the prevalence and location in the proteome 
of PTMs such as glycosylation, phosphorylation, sulfation, and proteolysis, fewer groups have 
tried to decipher oxidation post-translational modification and more specifically the formation of 
methionine sulfoxide. Madian et al. isolated sixty-five carbonylated proteins from plasma of male 
subjects. They also identified that in addition to the carbonylation, the proteins bore an oxidative 
modification and that methionine oxidation was the predominant followed by tryptophan oxidation 
(52). Ghesquière et al. studied methionine bound oxidation PTM in vitro using human Jurkat cells 
stressed with hydrogen peroxide. They identified over 2000 oxidation sensitive Met residues 
mapped to more than 1600 different proteins (41). Hsieh et al. studied the global Met oxidation 
changes of proteins in photofrin-mediated photodynamic therapy (PDT) in human carcinoma 
A431(53). They observed 431 Met residues linked to 302 proteins that suffered from severe 
oxidation. In a time-course study monitoring protein-bound Met oxidation in Bacillus cereus, 
Madeira et al. detected total of 8720 and 3417 Met(O) peptides in the cellular proteomes and 
exoproteomes, respectively (54).  
     Albumin represents the most abundant serum protein with a normal concentration ranging from 
35-50 g/l (55-57). Human Serum Albumin (HSA) participates in a multitude of functions such as 
transporting of molecules, maintaining osmotic pressure and serum redox state in the extracellular 
fluids (58-60). Furthermore, HSA is the most important antioxidant in plasma (61-63). Albumin 
is synthesized in liver with a half-life of ~27 days. HSA is single non-glycosylated polypeptide, 
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66438 Da, organized in three domains I, II and III each of which is comprised of A and B subunits. 
About 67% of albumin structure is α-helix It contains a single polypeptide chain of 585 amino 
acids. The structure owns 35 Cys residues forming 17 disulfide bridges with a single free Cys34 
that constitutes about 80% of all free thiols in plasma and it is therefore considered as quantitatively 
important oxygen scavenger in plasma (57,60,64,65). A study conducted by Finch et al. concluded 
that Cys34, Met123, Met298, Met446 and Met548 are the main oxidation sites within the structure 
of HSA (66).  
     The exogenous factor of cigarette smoke (CS) is rich in free radicals and causes serious 
oxidative stress. Tobacco smoke contains over 4,000 components, of which over 1,000 are very 
toxic chemicals such as (3,4-benzopyrene, heavy metals, free radicals, hydrogen cyanide, nitrogen 
oxides and N-nitrosamines) which are proven carcinogens (67-71). The response of the human 
body to stressing factors can be studied in its protein expression profile. Therefore, identifying 
changes in protein expression upon smoking will lead to understanding physiological responses 
due to smoking. Reznick et al. studied carbonyl (the appearance of carbonyl groups in the structure 
of proteins such as aldehydes or ketones due to oxidation) formation in plasma proteins of smokers. 
They found that isolated albumin and creatinine kinase exposed to CS showed much faster 
carbonyl formation than did the whole plasma (72). Yeh et al. found that protein carbonyl levels 
was higher among current smokers compared to former smokers, but the difference did not attend 
statistical significance (68). D’Anna et al. examined changes in proteome profile of lung fibroblast 
exposed to CS extract. Eleven proteins demonstrated changes, of which, seven were shown to be 
significantly higher and the remaining proteins were lower in cells exposed to CS (73). In a 
different approach, Kulikowska (74) et al. measured the concentration of the genotoxic reagent (8-
hydroxy-2'-deoxyguanosine) in the urine of smokers. They estimated a 3-fold increase in the 
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concentration of the reagent urine samples of smokers. Witherell et al. also noticed an elevated 
levels of oxidative DNA adduct 8-hydroxy-2'-deoxyguanosine excreted in urine after infection 
with Helicobacter pylori (75). A study conducted Panda et al. confirmed that the tar phase of CS 
is responsible for oxidation of microsomal proteins in vitro and the oxidized proteins were rapidly 
degraded by the action of proteases found in the microsomes (76). Clerici et al. observed an 
impaired ligand-binding capacity of albumin oxidized with CS (77).  
     In brief, proteome analysis still requires further expansion in order to display its full potential 
to become the predominant tool used in clinical diagnosis. However, increasing number of 
proteomics studies especially those recruited larger number of patients clearly demonstrates 
diagnostic accuracy. It might take long years for the full exploration of urinary proteome. A crucial 
question would be whether the focus should be turned into exploring the whole proteome of urine 
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Separation and analysis methodologies to expand the urinary proteome and 
comparison of smokers and non-smokers 
2.1 ABSTRACT 
      The urinary proteome is an attractive candidate for the discovery of biomarkers to diagnose 
and classify health conditions because of the non-invasive collection procedure. However, 
protocols developed for the analysis of the urinary proteome have limitations both in identification 
of proteins and eliminating false positives. Urine was collected from 40 adults (24 smokers and 16 
non-smokers). SDS-PAGE gel electrophoresis was followed by tryptic digestion, and then 
separation and identification by HPLC-MS/MS. Correspondence with predicted retention times, 
MS/MS sequence information, and a minimum of two tryptic peptides were required to reduce 
false positives. Proteins were matched to 1023 UniProtKB identification numbers, 467 of which 
have not been previously reported in the human urinary proteome. Gene ontology showed many 
were originally localized in the extracellular compartment but large numbers also originated 
intracellularly. Two proteins, annexin A1 and fatty acid binding protein 5 (FABP5), had 
statistically significant, after correction for multiple hypothesis testing, higher levels in urine of 
females. While proteins were found more commonly or at higher levels in the smoking or non-
smoking population, after multiple hypothesis testing correction, these differences are not 
statistically significant. This lack of significant smoking related differences is in contrast to several 







      Identifying protein biomarkers specific for different diseases using biological fluids is of 
great interest. Due to the ease and non-invasive nature of urine collection, this body fluid 
provides an alternate to blood plasma as a potential source for disease diagnosis and monitoring 
(1-3). In addition to potentially monitoring general health conditions, urine may provide more 
specific information about kidney function and disease (4-7).   
     Protein excretion in the urine of healthy individuals is ~150 mg/day (8,9) but the high 
abundance proteins serum albumin and IgG can complicate analysis of lower abundance proteins. 
Several separation approaches have been employed in the field of urinary proteomics. 
Identification by mass spectrometry has advanced continuously and emerged as a prominent tool 
for proteomic bioanalysis (10), including application to the study of the urinary proteome (8,11-
19).  However, each new study finds previously unidentified proteins in urine, implying that more 
remain to be discovered. 
     The emergence and development of spectral library search and bioinformatics tools for 
complements MS-based proteomic studies is assisting proteomic efforts in identifying and 
quantifying proteins and their post-translational modifications in biological samples (20-22).  
Advanced software packages increase the confidence in protein identification through the use of 
several statistical methods.  
     Smokers suffer from many illnesses linked to smoking and several studies have examined the 
proteomes of smokers in comparison to non-smokers (23-37), usually in sputum or blood samples.  
To the best of our knowledge only two studies (38,39) have examined differences in abundance of 
proteins in the urine of smoker and non-smokers and that on limited numbers of proteins and 
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individuals. As part of a larger study to determine differences in post-translational modification of 
proteins in smokers and non-smokers, we felt it appropriate to apply the latest instrumentation and 
analysis techniques to examine the occurrence of proteins in the urine of these two populations.  
 
2.3 MATERIALS AND METHODS 
2.3.1 Sample collection and processing 
     The University of Arkansas Institutional Review Board approved all experimental protocols 
using human subjects. First or second morning urine samples of at least 100 mL were obtained 
from forty individuals (Table 1 and Supporting Information Table S1). Immediately after sample 
collection, one protease inhibitor cocktail tablet (Millipore Sigma, SIGMAFAST containing 4-(2-
aminoethyl) benzenesulfonyl fluoride, trans-epoxysuccinyl-L-leucylamido (4-guanidino), butane, 
bestatin, leupeptin, aprotinin, and sodium EDTA) was added. Samples were stored at 4°C for no 
longer than 2 hours prior to centrifugation at 4°C for 20 minutes in a Sorvall GS3 rotor at 4000 
rpm (1700 RCF) to remove particulates. One hundred ml of the supernatant was transferred to six 
15 ml 2000 Da MWCO centrifugal concentrators (Sartorius Vivaspin) and sample size was 
reduced to approximately 1 ml in each concentrator by spinning at 4700 rpm (3700 RCF) in a 
Sorvall SH-3000 rotor for 6-8 hours at 4°C.  The concentrates were combined into a single 
concentrator. Concentrators not used in the next step were rinsed with small volumes of 100mM 
ammonium bicarbonate (pH 7.8).  After this rinse solution was added to the combined concentrate, 
additional 100mM ammonium bicarbonate was added to bring the total volume up to 15 ml and 
this was centrifuged as before for approximately 4 hours to reduce the final volume to 1.5 ml; 1.5% 
of the original sample volume. Early experiments showed a steady decrease in the amount of 
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protein visible on gels with storage at -80° for more than a few days, so this concentrate was stored 
only overnight at -80° C.  
     On the next day, 200 microliters of the concentrate were desalted using C18 spin columns 
(Pierce). C18 columns were first prepared according to manufacturer’s directions by adding 200μL 
of activation solution (50% methanol). Columns were placed into a microcentrifuge (receiver) tube 
and centrifuged at 1500 × g for 1 minute. Activation was repeated then 200μL of equilibration 
solution (0.5% TFA in 5% acetonitrile (ACN)) was added and spun at 1500 × g for 1 minute. The 
equilibration step was repeated and then the concentrated urinary protein sample was loaded on 
top of the resin bed. Columns were placed into a clean microcentrifuge tubes and spun at 1500 × 
g for 1 minute. The flow-through was recovered and the binding step was repeated to ensure 
complete binding. 200μL of washing buffer (0.5% TFA in 5% ACN) was added to the columns 
and they were centrifuged at 1500 × g for 1 minute. The flow-through was discarded and washing 
was repeated. Finally, proteins were eluted with 20μL of 70% ACN and centrifuged at 1500 × g 
for 1 minute. The elution was repeated with another 20μL of 70% ACN and the combined eluent 
was flash frozen and dried under vacuum using a SpeedVac concentrator for 5-7 hours. The 
resulting protein pellets were dissolved in 300 μl of 100 mM ammonium bicarbonate (pH 7.8).  In 
a few cases these solutions were run immediately on a gel, but usually were frozen at -80° until 
the next day 
 
 2.3.2 One-dimensional SDS-PAGE and in-gel digestion of urinary proteins 
     Dissolved pellets were mixed in a 2:1 ratio with loading buffer (100 mM TrisHCl, pH 6.8, 4% 
SDS, 20% glycerol, 200 mM β-mercaptoethanol, 0.2% bromophenol blue). The mixture then was 
heated to 100°C for 5 minutes to denature and reduce the proteins. Equal amounts of the mixture 
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were then loaded into each well of a pre-cast tris-glycine, 4-20% acrylamide gradient gel (NuSep) 
and separated by SDS-PAGE gel electrophoresis in a BioRad MiniProtean Tetra at 150 volts for 
1.5 to 2.0 hours until the tracking dye reached the bottom of the gel. The gel was stained overnight 
with Coomassie dye prepped by dissolving 0.25 g of Coomassie brilliant blue R-250 in 90 ml of 
methanol: 10 ml of H2O and glacial acetic acid (1:1 v/v). The next day, after excess stain in the 
gel was removed by destaining briefly in methanol/water/acetic acid, the gel was cut into five 
bands using a clean razor blade as illustrated in Figure 1. Each band was further cut into 1 × 1mm 
pieces and transferred to clean microcentrifuge tubes. Most bands would fit in a single tube, but 
the larger D band and, occasionally, the C band were split into two or three microcentrifuge tubes 
because of larger gel volumes. Sufficient 50% 100mM ammonium bicarbonate/50% acetonitrile 
(ACN) was added to barely submerge the gel slices then incubated at 37°C for 30 minutes to 
remove the Coomassie stain bound to protein from the gel slices.  The liquid was removed and 




Figure 1.  Urinary protein separation by SDS-PAGE. 200 uL of 
concentrate was divided across all wells of a BIS-TRIS 4-20% 
gel. After electrophoresis, the gel was stained with Coomassie 
blue, cut into segments as shown in the figure, destained, 
reduced and alkylated, and then each segment was separately 




2.3.3 Reduction and Alkylation  
     Enough fresh tris-2-carboxyethylphosphine (TCEP) solution (5mM in 100mM ammonium 
bicarbonate, pH 7.8) was added to cover the destained gel slices which were then incubated at 
95°C for 10 minutes. The TCEP solution then was pipetted out and discarded. Freshly prepared 
100 mM iodoacetamide (IAA) in 100 mM ammonium bicarbonate solution was added so that the 
gel slices were completely covered and then incubated at 37°C for 15 minutes with shaking. The 
IAA solution was pipetted from the gel slices and discarded. Gel slices were rinsed with 50% 
100mM ammonium bicarbonate/50% ACN and incubated at 37°C for 15 minutes with shaking 
and the rinse solution was pipetted away. The rinse and removal were then repeated. 
 
2.3.4 Digestion 
     Gel pieces were immediately reduced in size after reduction and alkylation by adding 50μL 
99.9% ACN and incubating for 15 minutes at room temperature. ACN then was removed by 
pipetting and gel pieces were left to air dry for 5-10 minutes in the open microfuge tube.  
A stock solution was made from freeze dried porcine mass spectrometry grade trypsin (G 
Biosciences) in 100 mM ammonium bicarbonate (pH 7.8) at a concentration of 1 mg/ml. This 
stock was immediately diluted 100-fold in 100mM ammonium bicarbonate to a final trypsin 
concentration of 0.01 mg/ml. Aliquots of the final 0.01 mg/ml trypsin solution were either used 
immediately or stored at -80° for no more than one month before use.  
     The 0.01 mg/ml trypsin solution was added until the dried gel slices were covered. Tubes were 
incubated at 37°C for 24 hours. The digest solution was pipetted to a new microcentrifuge tube. 
Gel pieces were then extracted three times by adding 50μL of 50% ACN/50% water, 0.1% 
trifluoroacetic acid (TFA) and incubation at 37°C for 5-15 minutes. This extraction liquid was 
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combined with the digest solution. The combined solution was frozen with liquid nitrogen and the 
volatiles removed under vacuum over 2-3 hours using a Speed-Vac concentrator to produce a 
peptide pellet.  
 
2.3.5 Peptide desalting 
     Each pellet was dissolved in 50 μl of 2% TFA in 20% ACN.  If the volume of the pieces of a 
particular gel band required splitting it into to multiple tubes, the samples were combined at this 
step by using the same 50 μl to sequentially dissolve the pellets. Sample was desalted using C18 
spin columns as described above. After the eluent was vacuum dried, peptide pellets were 
dissolved in 0.1% formic acid (FA) and stored at -80°C until LC-MS/MS.  
 
2.3.6 Analysis of the digest via ESI-LC-MS/MS 
     Digests were analyzed by ESI-LC-MS/MS. Data dependent analysis (DDA) for the in-gel 
trypsin digested samples were performed by using an Agilent 1200 series micro flow HPLC in line 
with Bruker Amazon-SL quadrupole ion trap ESI mass spectrometer (QIT-ESI-MS). Tryptic 
peptides were separated by reverse-phase high-performance liquid chromatography (RP-HPLC) 
using a Zorbax SB C18 column, (150 × 0.3 mm, 3.5 µm particle size, 300 Å pore size, Agilent 
Technologies), with a solvent flow rate of 4 µL/minute, and a gradient of 5%–38% consisting of 
0.1% FA (solvent A) and ACN (solvent B) over a time period of 320 minutes. As indicated in 
Table S1 (Supporting Information), some fractions were run multiple times.  All the ESI-MS 
analyses were performed in a positive ion mode using Bruker captive electrospray source with a 
dry nitrogen gas temperature of 200°C, with nitrogen flow rate of 3 L/minute. LC-MS/MS data 
were acquired in the Auto MS(n) mode with optimized trapping condition for the ions at m/z 1000. 
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MS scans were performed in the enhanced scanning mode (8100 m/z/second), while the collision-
induced dissociation or the MS/MS fragmentation scans were performed automatically for top ten 
precursor ions with a set threshold for one minute in the UltraScan mode (32,500 m/z/second).  
 
2.3.7 Data analysis 
     Protein identifications were performed via MASCOT (Matrix Science, London, UK) (40) 
searching all mass spectra data against human protein entries obtained from UniProt (41). Scaffold 
(version Scaffold_4.8.4, Proteome Software Inc., Portland, OR) was used to validate MS/MS 
based peptide and protein identifications. Peptide identifications were accepted if they could be 
established at greater than 80.0% probability to achieve an FDR less than 1.0% by the Peptide 
Prophet algorithm (42). Protein identifications were accepted if they could be established at greater 
than 5.0% probability to achieve an FDR less than 1.0% and contained at least 2 identified 
peptides.  Protein probabilities were assigned by the Protein Prophet algorithm (43). Proteins that 
contained similar peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were 
grouped into clusters. Proteins were annotated with GO terms from goa.gaf (downloaded Sept. 7, 
2017). (44).  Protein levels in populations (smoker vs. non-smoker, heavy smoker vs. non-smoker, 
and female vs. male) were compared using the spectral counting method in Scaffold, normalizing 






2.4 RESULTS AND DISCUSSION 











aHeavy smokers are those currently smoking 5 or more cigarettes a day, light smokers are those 
who are currently smoking at least once a week, but less than 5 cigarettes a day, non-smokers are 
those who have never smoked or not smoked in over 18 months. Sample donors are grouped by 
their age in years at time of sample collection. Number is the number of individuals in the study 
who meet the criteria to the left in the table. 
  
     Slightly over one thousand UniProtAC IDs were identified in urine samples from 24 smokers 
and 16 non-smokers. The distribution of sample donors by gender, smoking status, and age range 
is shown in Table 1 with more detailed information found in Table S1. These 1023 proteins were 
identified by Scaffold in the UniProt database with high confidence as a minimum of two tryptic 
peptides from each protein, with one or more being unique to that protein, was required, falsely 
identified proteins were reduced by performing a decoy database search, as described elsewhere 
(45), and the strictest threshold, a 1% False Discovery Rate, available in Scaffold was adopted. 
The Scaffold-assigned probability of identification was 95% or higher for 788 UniProtACs 
Sex Group Age range Number 
Female 
Light smoker 30-40 2 
40-50 1 
Heavy smoker 20-30 1 
30-40 3 
60-70 1 




Light smoker 18-20 1 
20-30 3 
30-40 5 









(77.03%). Only two peptides were detected for just 61 proteins, and just three peptides were found 
for 20 more.  The remaining 942 identifiers each had four or more peptides recognized.  The 
complete list of 1023 UniProtACs is found in Table S2 (Supporting Information). Of these 1023 
accession (UniProtAC) numbers, 1002 were successfully mapped to UniProt Knowledge Base 
(UniProtKB) identifiers. Six of the unmapped UniProtAC entries were fragments of 
immunoglobin variable regions and the remaining three unmapped were merged with other 
UniProtKB entries. Eleven were mapped to obsolete entries. Of the 991 active UniProtKB entries, 
754 were mapped to 623 genes.  This latter number, in many respects, may be the most reliable 
estimate of unique, non-redundant gene products.  Of the 991 active UniProtKB IDs, 431 were 
reviewed and 560 are currently unreviewed. Once our data was mapped to UniProtKB there were, 
for example, eight IDs for unreviewed entries for serum albumin in addition to the one reviewed 
entry.  Two of the unreviewed entries map to the ALB gene while the others are not mapped to 
any gene.  Presumably all nine entries in this case represent a single protein product. However, 
this case is an extreme and not all unreviewed entries are duplicates of a reviewed entry.  Scaffold 
clusters related proteins, in the case of the data here resulting in 467 groups.  However, in some 
cases, the program is combining closely related, but distinct proteins, such as the lactate 
dehydrogenase A and B chains, into a single cluster. The lack of automated tools to reliably remove 
redundant entries without dropping non-redundant entries led us to use the complete list for most 






     The identified proteins were subjected to Gene Ontology (GO) analysis (46,47) in Scaffold to 
determine typical subcellular localizations. Proteins normally localized in the extracellular region 
were 37.7% of those found. However intracellular proteins were well represented with cytoplasmic 
proteins being 28.1% of those detected and proteins originating in intracellular organelles were 
26.6%. Proteins localized to membranes comprised 20.6% of those identified. Gene ontology 
molecular function terms showed that 31.9% of the proteins detected had some sort of a binding 
function. Proteins with catalytic activity were also abundant (14.7%). Thirty-six uncharacterized 
(putative) proteins were observed in the current study.  
     The concentration and purification techniques were chosen to result in intact or large fragments 
of proteins being identified. The smallest protein chains found were the light chain of inter-alpha-
trypsin inhibitor at 5.7 kDa and beta defensin 1, which after processing is just 3.9 kDa.  The largest 
proteins found were titin, with a molecule weight as high as 3,816 kDa and mucins 5AC and 5B 
at 583 kDa and 595 kDa respectively, without considering any glycosylation.  For larger proteins, 
the percent coverage was, not surprisingly, often low so these may represent the detection of large 
fragments of very large parent proteins.  The median size of the parent proteins detected was 
approximately 45 kDa. These sizes are predicted for the intact protein and the methods employed 
may not allow separation and identification of isoforms such as transcriptional splicing variants or 
post-translational proteolytic cleavages. 
     Eighteen proteins were detected in the urine of all individuals and 74 proteins were found in at 
least 90% (≥36) of the individuals.  Approximately one half of the proteins were found in ten or 
more individuals.  Others were found in relatively few individuals.  Approximately one fifth of the 
proteins, while scattered throughout the various study participants, were detected in just a single 
person.  Most of these are proteins that are presumably present in more individuals and could be 
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detected if targeted, but low abundance prevented more frequent detection in the broad survey 
undertaken here.   
     Other studies (8,11-19) have previously explored the human urinary proteome and it might be 
wondered whether anything new remains to be learned. These studies are summarized in Table S3 
(Supporting Information) and, when converted to UniProt and duplicates are eliminated, 11,551 
unique UniProtKB ACs have been previously reported in human urine. Those 11,458 mapped to 
11,473 UniProtKB IDs, of which 8,561 were reviewed and 2,419 were unreviewed. The majority, 
10,481, of the 11,473 identifiers were successfully mapped to 8,867 genes. While many of the 
previous studies have detected more proteins overall than the results presented here, the present 
study is among the largest yet performed in terms of the number of individuals examined.  The 
fact that one fifth of the UniProtKB IDs identified in the work presented here were each found in 
only a single individual implies that a complete description of the low abundance or rare proteins 
that can be found in human urine may still be incomplete.  Indeed, this proved to be the case.  Out 
of the total of 1023 different UniProtKB IDs reported here, 466 (45.6%) have not been previously 
reported in other proteomic studies of human urine.  Of the 431 proteins that were identified in the 
current study and that are reviewed entries in UniProt, just eight had not been previously reported.   
However, of the 623 genes that entries found in the present study were linked to, 548 genes were 
among the 8,867 genes linked to entries that have been previously reported in urinary proteomic 
studies.  Therefore, 75, or about one sixth of all the protein gene products we found, are newly 
reported here. These proteins are listed in Table S4 (Supporting Information). Roughly half, 33, of 
these gene products are identified by Scaffold with a probability of greater than 95% and most are 
found in multiple individuals. The fact that the vast majority of these novel gene are not curated 
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entries in UniProt lends credence to the general idea that these are low abundance proteins for 
which comparatively little information about physiological roles is available.   
2.4.1 Comparison of protein levels and occurrence in smokers and non-smokers  
     Several studies have linked changes in levels of specific protein expression in cigarette smokers 
(48-51). However, little is known about the impact cigarette smoke may have on the level of 
plasma proteins, the immediate source of most proteins found in urine, more generally. It is no 
surprise that the total concentration of protein in urine varied widely. The total amount of protein 
was estimated using eight pictures of dyed gel smokers and a similar number for non-smokers.  
The total intensity was measured using the ImageJ application developed by NIH. The average 
ratio of dyed protein in smokers compared to non-smokers revealed an average doubled intensity 
of urine proteome in smokers (S/NS = 2.1) but with a standard deviation of nearly the same 
magnitude (1.8) these differences are clearly not statistically significant. We also compared the 
total mass spectrometry peak intensities of the entire proteome for all three replicates of each of 
the forty individuals used in the study. The ratio of the average intensities for smokers to non-
smokers was 2.6 but the standard deviation was 6.4, so again the difference in average total protein 
between the two populations is not distinguishable from that expected by chance.  
     These results give confidence that any variations in the level of any given protein that might 
occur between two populations are not likely due to variation in overall urine protein levels 
between those two populations.  The Scaffold software suite was used to determine differences 
between populations in the observed levels of each particular protein. Because of the large 
variation from sample to sample in total protein levels noted above, the level of each protein in 
each individual was normalized in Scaffold by the total spectrum count for that individual. Figure 
2A is a volcano plot, showing the differential abundance (fold change) of each protein in the urine 
 
 29 
of smoking and non-smoking populations versus the t-test probability for that protein.  Figure 2B 
is similar but compares non-smokers to the twelve individuals self-reporting as smoking five or 
more cigarettes a day (heavy smokers).  As can be seen in both plots a number of proteins have a 
p of less than 0.05, often taken as a cutoff for statistical significance. In Tables 2 and 3, a summary 
of the proteins meeting the more stringent cutoff of p ≤0.01 in Figure 2A and 2B, respectively, is 
given.  Of course, when examining over one thousand UniProtKD IDs as we do here, one would 
expect approximately 10 proteins in a randomly distributed sample to have p ≤0.01 and 50 or so 
with p ≤0.05.  So, not surprisingly, after applying the Benjamini-Hochberg multiple hypothesis 
testing correction (52), none of the proteins that are found at higher levels in either smokers versus 
non-smokers or heavy smokers versus non-smokers rises to the level of statistical significance, 





































































Figure 2.  Volcano plots of –Log10 p versus the fold change of protein level between the two 
populations. In 2A the populations are smokers (S) and non-smokers (NS), in 2B heavy smokers 
(HS, more than five cigarettes a day) are compared to non-smokers (NS), and in 2C males (M) and 
females (F) are compared. The dashed red line corresponds to a p value of 0.05 and the solid red 
line to a p value of 0.01. UniProtKB IDs with p ≤ 0.01 are shown in red and IDs found elevated in 







Table 2. Ratio of Protein Levels in Smoking and Non-Smoking Populations in Order of Statistical Significancea 
aSmokers (S) are those who are currently smoking at least once a week, non-smokers (NS) are those who have never smoked (n = 13) or not smoked in over 
eighteen months (n = 3). If the UniProtKB entry mapped to a gene, the gene ID is given as well. ND means not detected in the indicated population.  
UniProt Description 
UniProt 
Acc. No. p Fold S/NS 
   High in NS, low in S    
SUN domain-containing protein 1  GN=SUN1   SUN1 0.00019 0.20 
Keratin, type I cytoskeletal 13  GN=KRT13   K1C13 0.00092 0.07 
cDNA FLJ58780, highly similar to lysosomal-associated membrane protein 2 (LAMP2B) B4E2S7 0.00186 0.18 
Beta-actin-like protein 2  GN=ACTBL2   ACTBL 0.00208 0.28 
Putative beta-actin-like protein 3  GN=POTEKP ACTBM 0.00227 0.27 
Betaine-homocysteine S-methyltransferase 1  GN=BHMT   BHMT1 0.00266 0.17 
cDNA FLJ78503, highly similar to keratin 13 (KRT13)  A8K2H9 0.00327 0.09 
Keratin, type II cytoskeletal 3  GN=KRT3   K2C3 0.00384 0.16 
L-lactate dehydrogenase B chain  GN=LDHB   LDHB 0.00389 0.28 
Keratin, type II cytoskeletal 6B  GN=KRT6B   K2C6B 0.00406 0.34 
Keratin, type II cytoskeletal 4  GN=KRT4   K2C4 0.00566 0.08 
cDNA FLJ54604, highly similar to Betaine-homocysteine S-methyltransferase B4DPF0 0.00653 0.17 
Keratin, type II cytoskeletal 2 epidermal  GN=KRT2   K22E 0.00719 0.42 
Plasma serine protease inhibitor  GN=SERPINA5   IPSP 0.00791 0.43 
Prosaposin (Variant Gaucher disease and variant metachromatic leukodystrophy) Q53FJ5 0.00794 0.19 
Keratin, type II cytoskeletal 73  GN=KRT73   K2C73 0.00824 0.10 
Phosphoglycerate kinase 1  GN=PGK1   PGK1 0.00944 ND in S 
cDNA FLJ54596, highly similar to Proactivator polypeptide    B4DEK5 0.00945 0.11 
   High in S, low in NS    
Putative uncharacterized protein DKFZp686C02220 (Fragment)  GN=DKFZp686C02220   Q6N091 0.00236 3.4 













   High in NS, low in HS     
SUN domain-containing protein 1  GN=SUN1   SUN1 0.00662 0.21 
Plasma serine protease inhibitor  GN=SERPINA5 IPSP 0.00697 0.22 
Keratin, type II cytoskeletal 4  GN=KRT4  K2C4 0.00731 0.05 
Deoxyribonuclease-1  GN=DNASE1   DNAS1 0.00745 0.44 
Betaine-homocysteine S-methyltransferase 1  GN=BHMT   BHMT1 0.00936 0.06 
    
   High in HS, low in NS    
Putative uncharacterized protein DKFZp686G21220 (Fragment) GN=DKFZp686G21220 Q6N090 0.00022 ND in NS 
Putative uncharacterized protein DKFZp686L19235  GN=DKFZp686L19235   Q6MZV6 0.00102 2.4 
IGH@ protein  GN=IGH@   Q6P089 0.00108 2.4 
cDNA FLJ41981 fis, clone SMINT2011888, highly similar to Protein Tro alpha1 H,myeloma    Q6ZVX0 0.00133 2.3 
Putative uncharacterized protein DKFZp686J11235 (Fragment)  GN=DKFZp686J11235   Q6MZW0 0.00149 12.2 
Putative uncharacterized protein DKFZp686M08189  GN=DKFZp686M08189   Q6MZX9 0.00241 2.1 
cDNA FLJ55716, highly similar to Desmocollin-2    B4DLJ5 0.00309 3.6 
Complement decay-accelerating factor  GN=CD55   H7BY55 0.00393 4.0 
Desmocollin-2  GN=DSC2   DSC2 0.00717 2.9 
Myosin-reactive immunoglobulin light chain variable region (Fragment)    Q9UL83 0.00955 2.2 
Tyrosine-protein phosphatase non-receptor type substrate 1  GN=SIRPA   SHPS1 0.00988 2.3 
 
aHeavy smokers (HS) are those who were currently smoking at least five cigarettes a day, non-smokers (NS) are those who have never smoked or not smoked in 




     Two studies have previously examined the impact of cigarette smoking upon the urinary 
proteome. In the first published, Airoldi et al. (38) examined the urine pooled from ten non-
smokers and pooled from ten smokers, all male, using three replicate 2D electrophoresis gels for 
each pool to identify 165 spots present in all gels, followed by LC-MS/MS of the tryptic peptides 
of 6 spots that were significantly different in image analysis of the smoking and non-smoking gels. 
Pancreatic alpha-amylase, found in two distinct spots, S100A8, CD59, and inter-alpha-trypsin 
inhibitor heavy chain H4 were more abundant in smokers. One protein, zinc-alpha-2-glycoprotein, 
was the only protein less abundant in smokers.  Haniff and Gam (39) more recently looked for 
differences in band intensities in 1D protein gels between eight smokers, eight passive smokers, 
and 8 non-smokers. They identified two bands that differed consistently.  Using tryptic digests and 
MS/MS, they identified four proteins unique to smokers: pancreatic alpha-amylase, proepidermal 
growth factor, protein 4.1, and prostatic acid phosphatase.  Further one protein, plasma serine 
protease inhibitor, was found in both populations in a 4.879 S/NS ratio. 
     While we did not observe either pancreatic alpha-amylase or protein 4.1, the others were present 
in the samples.  The p values and ratios found in the present study for these proteins flagged in 
previous studies are summarized for non-smokers versus all smokers or heavy smokers in Table 
4.  In every case, and in contrast to the earlier work for all but one protein, we observed that the 
proteins in question were more abundant in non-smokers.  The exception is zinc-alpha-2-
glycoprotein which was the sole protein previously found less abundant in smokers.  While our 
data agree with this, we note that the ratio found in smoker and non-smokers is near one and the 
statistical significance very low indeed. While plasma serine protease inhibitor is the lowest p 
value found for these proteins in our study, it still does not rise to the level of statistical significance 




     Interestingly, a study of epithelial lining fluid showed decreased levels of S100A8 in acute 
response to smoking (24), a result in agreement with ours.  A study of the human placental 
proteome response to maternal smoking (29) also had a number of differences in protein levels 
between smokers and non-smokers that were in qualitatively similar to those we observed in urine, 
although most were not of particular statistical significance in our data. On the other hand, in 
studies of proteomic changes in response to smoke exposure in platelets  (26) or in plasma 
(25,30,53,54), relatively few of the proteins identified as showing significant changes in level 
between populations were detected in the present study, but none of those that were detected 
showed as statistically significant.  
     This is not to imply that previous work is unreliable.  Indeed, one of these studies of plasma is 
particularly noteworthy for examining the plasma of 1,686 study participants, and having great 
statistical power (53). Rather, we believe that while different levels of various proteins may well 
be found in the urine of smokers and non-smokers, the high variability of levels of each urinary 
protein from sample to sample and the relatively small differences in protein levels between 
smokers and non-smokers  (55,56) mean that a very large number of samples will be needed to 
find and confirm with any confidence that there are meaningful differences.
 




Table 4. Ratios of Urinary Protein Levels Between Populations in Present Study for Proteins Previously Discussed in 
Literaturea 
UniProt Description UniProt Acc. No. p Fold S/NS     p Fold HS/NS 
   Airoldi et al.       
CD59 glycoprotein GN=CD59 CD59 0.04016 0.36  0.06591 0.28 
Inter-alpha-trypsin inhibitor heavy chain H4 GN=ITIH4  ITIH4 0.15690 0.66  0.08926 0.45 
Protein S100-A8 GN=S100A8 S10A8 0.86680 0.91  0.91955 0.94 
Zinc-alpha-2-glycoprotein GN=AZGP1 ZA2G 0.90871 0.98  0.63374 0.90 
       
   Haniff & Gam       
Plasma serine protease inhibitor GN=SERPINA5 IPSP 0.00791 0.43  0.00697 0.22 
Pro-epidermal growth factor GN=EGF EGF 0.24304 0.71  0.15999 0.57 




aProteins in this table are those previously identified by either Airoldi et al. (38) or Haniff & Gam (39) as being significantly elevated 
or depressed in smokers relative to non-smokers and also found in our samples.  The ratio of protein levels found in smokers or heavy 




2.4.2 Comparison of protein levels and occurrence in females and males 
     In contrast, in the comparison of protein levels found in females and males, Figure 2C and 
Table 5, after correcting for multiple hypothesis testing, three identifiers in the UniProt database 
are flagged as being statistically significant at p ≤0.05.  Although we list the three identifiers 
returned from Scaffold’s search of UniProt, for reasons explained in more detail in the footnote 
below, there is strong reason to believe that there are really just two proteins due to the nature of 
the UniProt database.  Those two proteins are annexin A1 and fatty acid binding protein 5 
(FABP5).   
     Guo et al. (55) previously found that male and female urinary proteomes were distinguishable. 
They examined 7 males and 7 females and listed the 20 most significantly different proteins.  We 
detected six of those proteins and three showed the same qualitative reduction or elevation in one 
gender, while the other three did not.  Two of the proteins that qualitatively agreed were prostatic 
acid phosphatase and prostate-specific antigen, unsurprisingly elevated in males in both the earlier 
and present study.  However, the M/F ratio of 2.23 for prostatic acid phosphatase and 1.94 prostate-
specific antigen we observed did not have particularly high p values, 0.136 and 0.360 respectively.  
The fact that proteins that there is very good reason to believe are elevated in males do not show 
as statistically significant shows, again, that it is likely that there are real differences between levels 
of other proteins in the female/male and non-smoker/smoker populations that are masked 
statistically by the inherent noise in the data.  On the other hand, the protein of the six that we 
found the most statistically significant was myeloperoxidase with a M/F ratio of 0.056 and p = 
0.0044.  In the previous study, the M/F ratio was 5.81. Again, we interpret 
this to mean that highlighting as significant any difference in urinary protein levels between 




proteins.  This interpretation is buttressed by the fact that few of the proteins identified as specific 
to the pooled urine of 20 men or 20 women by Oh et al. (57) were detected in the present study, 
and none of those that were detected here had statistically significant different levels in males and 
females. 
     That caution may even extend to those proteins whose difference in level are flagged as 
significant even after correction for multiple hypothesis testing.  The present study finds FABP5 
as having the most significant difference between males and females. There is, to the best of our 
knowledge, no data about differences in the levels in human urine for this protein.  However, a 
study of human serum, the penultimate stop for proteins before urinary secretion, found no 
significant difference in FABP5 levels between men and women (58).  
     The other protein flagged as significantly different, after multiple hypothesis correction, was 
annexin A1. Other work supports the idea that this may be a real difference.   Sun et al. (59)  
examined the urine of 3 men and 3 women and found annexin A1 in none of the men but only in 
the urine of a single female. Although in the blood rather than urine, premenopausal women 
expressed higher levels of annexin A1 on the surface of their circulating polymorphonuclear cells 
(60) than did men.  Similarly, annexin A1 was identified as being significantly higher in human 








Table 5. Ratio of Protein Levels in Female and Male Populations in Order of Statistical Significancea 
UniProt Description UniProt Acc. No. p Fold F/M 
Fatty acid binding protein 5 (Psoriasis-associated)  GN=FABP5   E7DVW5  0.00001 69.7 
Annexin  GN=ANXA1   B5BU38 0.00002 12.6 
Annexin (Fragment)  GN=ANXA1   Q5T3N1 0.00003 21.7 
Beta actin variant (Fragment)    Q53G99 0.00032 5.0 
Actin-like protein (Fragment)  GN=ACT   Q562Z4 0.00032 4.6 
cDNA FLJ52761, highly similar to Actin, aortic smooth muscle    B4DUI8 0.00085 15.2 
cDNA FLJ42347, highly similar to Actin, gamma-enteric smooth muscle    B3KW67 0.00125 14.0 
cDNA FLJ57283, highly similar to Actin, cytoplasmic 2    B4E3A4 0.00215 11.7 
Glyceraldehyde-3-phosphate dehydrogenase  GN=GAPDH   G3P 0.00223 5.8 
Annexin  GN=ANXA2   A0A024R5Z7  0.00232 10.6 
Protein S100-A9  GN=S100A9   S10A9  0.00233 5.3 
Alpha-enolase  GN=ENO1   ENOA 0.00350 3.8 
Epididymis luminal protein 176  GN=HEL-176   V9HVZ7 0.00578 3.2 
Pyruvate kinase PKM  GN=PKM   KPYM 0.00829 6.4 
Cystatin-B  GN=CSTB   CYTB  0.00856 21.8 
cDNA FLJ53963, highly similar to Leukocyte elastase inhibitor    B4E3A8 0.00922 20.1 
Histone H2A.V  GN=H2AFV   H2AV  0.00979 ND in M 
 
aThe three identifiers that remain significant at the p ≤0.05 level after correction for multiple hypothesis testing are italicized. If the 





     Our strategy in processing and analysis of urine samples resulted in a set of proteins among 
which about 20% were identified for the first time. More low abundance proteins likely remain to 
be identified in human urine. In contrast to earlier work, no statistically significant differences 
were found in the levels of proteins in the urine of non-smokers compared to either smokers or just 
heavy smokers. Indeed, in many cases the ratios found here were qualitatively inverted relative to 
earlier work.  However, annexin A1 and fatty acid binding protein 5 (FABP5) both are significantly 
elevated in females compared to males. While other differences in protein abundance between 
these various populations may exist, the degree of difference is low enough that studies of larger 
numbers of individuals and greater statistical power will be required to tease them out.  There are 
undoubted advantages to the collection of urine compared to other sources of human protein, but 
it seems doubtful that variations of specific protein levels in urine are likely to be tremendously 
useful as a clinical tool because of the statistical noise.  Even for research purposes, using protein 
sources with less inherent individual variability will often make up for the collection difficulties if 
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2.7 SUPPORTING INFORMATION 









Oh et al. (57) 2004 40 113 UniProt Voyager DE-STR MALDI-TOF mass spectrometer 
Castagna et al. (62) 2005 8 383 IPI 
Fourier Transform-Ion Cyclotron Resonance (FT-
ICR) Mass Spectrometry 
Sun et al. (63) 2005 10 226 GI 
I-DE, 1-D LC/MS/MS, direct 1-D Lc/MS/MS and 2-
D LC/MS/MS 
Adachi et al. (8) 2006 10 1543 IPI LTQ-Orbitrap, LTQ-FT 
Kim & Moon (64) 2009 29 245 IPI nLC-ESI-MS/MS, IEF-AF4 




Gonzales et al. (18) 2009 8 1132 GI LTQ 
Sun et al. (59) 2009 6 422 IPI, Swiss-Prot LCQ Deca XP1 IT mass spectrometer 
Li et al. (16) 2010 3 1310 IPI LTQ-Orbitrap, LTQ-Orbitrap Velos 













Nagaraj & Mann 
(66) 
2011 7 808 UniProt LTQ-Orbitrap 
Tyan et al. (67) 2011 16 2782 NCBI nano-HPLC/ESIMS/ MS 
Marimuthu et al. 
(15) 
2011 24 1823 GI LTQ-Orbitrap Velos 
Raj et al. (68) 2012 4 378 UniProt LC/ESIMS/ MS for iTRAQ 
Wang et al. (17) 2012 9 3280 UniProt LTQ-Orbitrap Velos 
He et al. (69) 2012 200 1641 IPI 
Four different fractionation techniques including in‐
gel, 2D‐LC, OFFGEL, and mRP) coupled with 
HPLC‐Chip‐MS/MS 
Zheng et al. (14) 2013 10 2579 IPI LTQ-Orbitrap Velos 




triple quad LC/MS/MS on-line connected to nano-
chromatography in a Chip-format configuration 
(ChipCube interface, Agilent Technologies) and 
1200 Series LC Modules 








Swiss-Prot LTQ-Orbitrap Velos 













Di Meo et al. (71) 2016 6 2091 Swiss-Prot Q-Exactive Mass spectrometer 
Zhao et al. (12) 2017 24 6085 Swiss-Prot 
1D & 2D LC-MS/MS, gel-eluted liquid fraction 
entrapment electrophoresis/liquid-phase isoelectric 
focusing 









Methionine Sulfoxide Proteome and the Impact of Smoking 
3. 1 Abstract 
     There is accumulating evidence that high levels of methionine sulfoxide (MSO) has been found 
in plasma proteins in smokers compared to non-smokers. Oxidation plays a key role in the 
degradation of proteins. While oxidation may directly interfere with activity, the extent to which 
oxidation affects protein turnover is less clear. Here we quantify methionine sulfoxide containing 
tryptic peptides in plasma proteins of cigarette smokers versus non-smokers. Using Mass 
spectrometry-based platforms, we present the first in vivo human methionine sulfoxide proteome 
in addition to illustrating the impact of smoking.  
     To determine level of oxidized serum proteins cleared in the urine of smokers and non-smokers 
with a focus on MSO formation in human serum albumin (HSA) protein.  
     Urine samples were collected from smoker and non-smokers participants. Proteins were 
concentrated and concentrates then were subjected to separation via SDS-Gel electrophoresis 
technique. Gel was cut out into five sections including the band representing intact HSA. Gel 
sections then were digested with trypsin. Levels of MSO in the resulting peptides were assessed 
by mass spectrometry. Data analysis was performed using Skyline software package.  
     A group comparison between non-smokers (control) and smokers showed a slight increase in 
the levels of MSO found in intact HSA of smokers relative to non-smokers.  Regions of gels with 
proteins of lower mass than intact HSA showed that degraded fragments of HSA in urine of both 
smokers and non-smokers have higher levels of MSO than oxidation level found in the intact HSA 
band.  HSA in smokers has statistically significant higher levels of MSO than HSA in non-




HSA.  At the moment, it is not possible to say unequivocally whether oxidized HSA is more likely 


























     Reactive oxygen species (ROS) are naturally produced as intermediates during cellular 
respiration (1). Although low quantities of antioxidants are required to protect the body from 
deleterious effects of ROS, , an imbalance between the formation of ROS and detoxification results 
in so called “Oxidative Stress” (2,3). ROS are involved in several cellular processes including 
signal transduction (4,5), and antimicrobial action of immune system (6,7). On the other hand, the 
destructive effects of ROS on different macromolecules, including nucleic acids and proteins are 
known to be important contributors to degradation of proteins (3,8). Oxidative stress in proteins 
results in the modification of amino acids or the carbon skeleton of the peptide which consequently 
leads to fragmentation of the polypeptide chain predisposing the protein to structural and 
functional alterations (9-13). Plasma contains a small group of proteins exhibiting very high 
abundance, e.g. albumin, and a much larger group of proteins represented in lower abundances. 
While proteins are among the main targets of ROS, sulfur containing amino acids (Cys and Met) 
out of the twenty amino acids are potential reductants due to the electronegativity of the thiol group 
in the structure (14-16). Protein thiol concentrations are in the 400-600 uM range (17). Methionine 
is considered among the most hydrophobic residues in proteins and it resides mainly in the interior 
hydrophobic core or embedded in the lipid bilayer membrane and therefore fairly protected from 
oxidative stress (18-20). Meanwhile, surface exposed Met residues can be easily oxidized, 
subsequently, they are well known for their ROS scavenging actions (21-23).  
     The major product that arises from oxidation of Met is methionine sulfoxide (MSO). Further 
oxidation of Met results in the formation of methionine sulfone, which occurs to a much lesser 
extent (1) (Fig. 1). Mechanisms of MSO generation depend on the type of oxidant. Hydrogen 




electron oxidation. Metal ions such as Fe3+ and HO. oxidative radicals utilize one electron 
oxidation mechanisms in generating MSO from methionine (24). Reaction of HO. with Met occurs 
at a rate constant of 7109 M-1 ∙ S-1, while the reaction of Met with H2O2 proceeds at a much slower 
rate, 210-2 M-1∙S-1 (25).  
     Conversely, MSO can be recycled back enzymatically to its reduced state via methionine 
sulfoxide reductases (MSRs). Thus, both components are important in the damage and repair 
mechanisms of proteins (26,27) Methionine sulfoxide is known to modulate several pathways e.g. 
activation of calcium/calmodulin dependent protein kinase II (CaMKII) in the absence of calcium 
and in activating transcription factors (28-30). Also, methionine sulfoxide has been linked to the 
etiology of several diseases including cardiovascular, renal, neurodegenerative and age-related 
diseases (24,26,31), and malignancies including liver and breast cancers (32-35). Oxidation of 
certain methionine residues has been linked to impairment of protein functions such as Met 388 in 
thrombomodulin resulting in decreased coagulation activity (36,37), and oxidation of both Met 33 
and 209 in Fc region of IgG1 impose negative consequences on the structure and stability of the 
protein (31).  
     Tobacco use is the leading cause of preventable death and diseases. It results in the death of 
approximately 500,000 Americans annually (38). Cigarette smoke is a complex mixture containing 
nearly 4000 chemicals (8), it also includes several reactive oxygen species (ROS) such as hydroxyl  
radical (HO.), superoxide anion (O2-.) and hydrogen peroxide (H2O2). Some of these species are 
highly reactive such as hydroxyl radical. It oxidizes almost all macromolecules. Most importantly, 
there is a well-established linkage between the disease of emphysema in smokers and methionine 




the binding site of α 1-antitrypsin destroys its ability to bind elastase, consequently elastase activity 
may increase as a consequence of oxidative stress (40).  
 
Figure 1: Met is oxidized to Met sulfoxide by ROS and to Met sulfone at higher concentrations 
of these oxidants  
 
     Human serum albumin is a monomer with a molecular mass of ~ 66.5 kDa and it accounts for 
50% - 60% of total plasma protein. HSA has six Met and 35 Cys residues forming 17 disulfide 
bonds (Fig. 2). HSA is regarded as an important antioxidant in plasma due to the single free 
cysteine (Cys 34) (35,41). In addition to its antioxidant properties, HSA plays a significant role in 
binding and transporting multiple ligands such as cholesterol, fatty acids and bile pigments, in 







Figure 2: Methionine residues in the structure of HSA. Residues are shown in red spheres and 
are labeled according to their sequential order. PDB ID: 1BMO 
 
 
     Proteomic approaches such as 2D-electrophresis and mass spectrometry (MS) represent robust 
tools for identification and quantitation of post translational modifications (PTMs). Modern 
instruments possess the resolution to measure the shift in the mass caused by a single oxygen 
molecule (43). Mass spectrometry has evolved as the prevalent technique for the identification and 
characterization of proteins structure as well as quantification of PTMs. Oxidative PTM of proteins 
are of special interest as they appear to play an important role in many diseases and metabolic 
dysfunctions. Tandem MS (MS/MS) based techniques are powerful in localizing oxidation 
modification in proteins (44). It enables accurate measurement of mass to charge ratio (m/z) of 
ionized analytes. Since oxidation  PTM alters the mass of a protein it changes the m/z ratio of the 
protein or peptide containing the oxidized amino acids (45).  
     Biofluids (e.g. urine and blood) have been used as valuable sources for proteomics analysis 
over decades due to their relative stable composition and the convenience of obtaining. It has been 




studies dependent on urine samples demand a sensitive detection of total proteins. A study reported 
that different methods may respond inadequately for each protein present in a urine sample, 
consequently, standardization would be unachievable. This is mainly because of the complexity of 
urine and partially due to the fact that conformational changes in plasma proteins alter their 
filtration rate of the kidneys. In addition, proteins in urine (e.g. HSA) are exposed to a wider range 
pH than found in plasma (48).  
 
3.3 MATERIALS AND METHODS 
     Procedural details including urine sample collection and processing, in-gel protein digestion, 
peptide desalting, and analysis of the digest via ESI-LC-MS/MS are extensively discussed in 
chapter 2. A schematic overview of overall procedure used in the current study is given in Fig. 3. 
 
3.3.1 Data analysis 
     Protein identifications were performed via MASCOT (Matrix Science, London, UK) (49). 
searching all mass spectra data against human protein entries obtained from UniProt (50). 
Statistical analysis and extracting MS1 intensities of the identified tryptic peptides were achieved 
with Skyline-daily software package, an open source Windows client application for both Data 
Independent Acquisition (DIA/SWATH) and targeted Data Dependent Acquisition (DDA) with 




the number of replicates and the condition of samples (healthy and disease representing non-
smoker and smoker samples, respectively) (51).  
 
Figure 3. Schematic overview of the overall procedure used in the current study 
 
3.3.2 Targeted proteomics and high accuracy protein quantitation 
     Targeted protein work was performed using a Shimadzu UPLC-20A coupled to a Shimadzu 
8050 triple quadrupole ESI-MS with heated probe. Tryptic peptides were separated by reverse-
phase ultra-high-performance liquid chromatography (RP-UPLC) compatible Shimadzu C18, 1.9-
micron particle size, 50x2.1 mm column (SN # 16041880T), with a solvent flow rate of 0.3 
mL/minute, and a gradient of 5%–90% consisting of 0.1% FA (solvent A) and 0.1% FA in ACN 
(solvent B) over a time period of 10 minutes.  Sequence specific fragment ion intensities from all 
six Met containing (oxidized and reduced) tryptic peptides from HSA were used in the protein 




fragment ions derived from the precursor tryptic peptides were targeted to operate at a certain 
specific retention time interval predicted by in-house retention time library. This library was 
generated using oxidized peptides. (Biomatik, Wilmington, DE). The library for the reduced 
peptides was generated using correlation of relative hydrophobicity of the tryptic peptides with 
their retention times (RT). While the RT correlated well within 99% confidence, a sufficient 
number of sequence specific fragment ions were present to use as basis for identification of the 
tryptic peptide by MS/MS alone. Further specificity and confidence were achieved by 
incorporating RT prediction.  
 
3.4 RESULTS AND DISCUSSION 
     Urine samples were grouped according to sex, smoking status and age groups (chapter 2). 
Peptide settings used in Skyline allowed a maximum of one missed tryptic cleavage in identifying 
peptides ranging from 8-35 amino acids with carbamidomethylation of Cys as a fixed modification 
and oxidation of methionine as variable modification. The search resulted in identification of 198 
proteins (table S1) harboring 392 methionine sulfoxide (MSO) containing peptides (table S2). 
About 70% of the proteins were found containing a single peptide with MSO. Skyline enables 
prediction of retention times using a function of sequence specific retention calculator (SSRCalc.) 
proposed by Krokhin and Spicer (52) (Fig.4). A combination of database search of spectral library 









Figure 4. Skyline uses the retention times of the peptides to normalize the times of the replicates 
to get the maximum achievable linear regression. 
 
     The aim of using DDA maximize protein coverage and minimize redundant peptide precursors 
ions (53,54). However, studies have pointed technical issues arises using DDA. It has been shown 
that reproducibility of peptide identification among technical replicates results in overlaps (55,56). 
Bateman et al. addressed the issue of maximizing peptide identification using data-dependent 
acquisition (DDA). They proposed an analytical work flow to combine DDA with retention time 
(RT) aligned extracted ion chromatogram. They observed an increase in peptide identification 
using mouse blood plasma up to 30.5% due to the comparison of peptide MS1 extracted ion 
chromatogram followed by retention time alignment of co-identified peptides. Further, they found 
that the method is useful for quantitative measurements using dilution series of known standards 






3.4.1 Comparison of methionine sulfoxide levels in smokers and non-smokers 
      To graphically represent oxidation in tryptic peptides, we generated the so-called volcano plot 
representing intensities acquired for all forty bio-samples (16 non-smokers and 24 smokers), in 
which log10 of the adjusted p-value for the difference in intensities between smokers and non-
smokers is plotted against log2 of the actual fold changes between the two categories using non-
smokers as reference. As it can be readily seen in Fig. 5 (a, b), a significant increase in the amounts 
of oxidized peptides from a wide variety of proteins. The large number of peptides with significant 
fold changes compared those that were not found significant is a quick way to illustrate increased 
oxidation of Met in smokers compared to non-smokers. In no case is a methionine found to be 
significantly more oxidized (down-regulated) in non-smokers than smokers. Testing results (table 
S2) show nearly 37% of the total identified proteins demonstrate elevated levels of MSO in 
smokers.  
     While previous studies examined biomarkers of oxidative stress and others investigated effects 
of specific methionine oxidations, there is a lack of sufficient evidence illustrating the proteome 
of oxidized methionine residues.  Zurbig et al. (58) analyzed the low molecular weight urinary 
proteome of 324 healthy individuals aging between 2-73 looking for biomarkers indicating kidney 
aging and chronic kidney disease. The study focused on 49 peptides reflecting aging among which, 
fragments of collagen alpha-1 were predominant. They also identified three peptides for 
uromodulin that was spotted in our study with significant fold change in smoker with a fold change 
of 2.93 (p-value = 0). Surprisingly, the majority of peptides they identified were not methionine 
containing fragments. Similarly, several proteins were found to be significantly higher in an 




including serum albumin, uromodulin and apolipoprotein, each with several fragments (59). 
Oxidation of methionine 35 in Alzheimer’s amyloid beta-peptide 1-42 is shown to be associated 
with oxidative stress and neurotoxicity (60,61). Ghesquière et al. However, analyzed oxidation of 
methionine using human jurkat cellular inflammation as a model. So far, the study is regarded as 
the largest pool of protein-bound methionine oxidation (18). Other non-human protein-bound 
methionine oxidation were carried out using rats and Bacillus cereus (62,63).  
 
 
Figure 5: Volcano plot illustrates significant fold-changes of MSO. (Left) Significantly up-










     Higher levels of methionine sulfoxide were further confirmed via targeted proteomic approach 
using tryptic peptides of HSA. Serum albumin was identified in all bio-samples collected in the 
current study. The tryptic peptides containing all six methionine residues in HSA, length and 
masses are illustrated in table 1. A chromatogram of the peptides (oxidized and non-oxidized are 
shown in figure (6). MS intensities and spectral MS/MS spectral count acquired for HSA were 
used to draw a general picture of percent oxidation and redox ratios in both experimental and 
control populations, in addition to studying the effect smoking could have on protein turnover.   
      Targeted proteomics analysis of peak areas obtained for Met containing fragments (oxidized 
and reduced) of serum albumin agrees with the up-regulation of MSO in smoker compared to 
control, discussed in DDA. All six peptides were chosen for further analysis. First, peptides were 
confirmed via database search (Fig. 7). Three sequence specific fragment ions b9, and y7, y9 were 
considered for this approach. Intensity comparison of these fragments elucidated higher levels of 
MSO in smokers (Fig. 8). Group comparison of MSO in intact HSA smokers compared to non-




















 Table 2: Targeted proteomic data analysis reveals a significant fold change of methionine                      




Position Peptide sequence % Relative solvent 
accessibility  
2917.3229 311-337 SHCIAEVENDEMPADLPSLA ADFVESK 37 
2593.2425 139-160 LVRPEVDVMCTAFHDNEETF LK 20 
2404.1709 470-490 MPCAEDYLSVVLNQLCVLHE K 24 
1623.7875 348-360 DVFLGMFLYEYAR 
 
15 
1342.6347 570-581 AVMDDFAAFVEK 
 
15 
1320.4905 106-117 ETYGEMADCCAK 21 
Peptide Fold Change p-Value (peptide) p-Value (protein) 
ETYGEMADCCAK 7.43  0.0049 
0.039 
LVRPEVDVMCTAFHDNEETFLK 3.51  0.0099 
SHCIAEVENDEMPADLPSLAADFVESK 4.13  0.0049 
DVFLGMFLYEYAR 2.9  0.0049 
MPCAEDYLSVVLNQLCVLHEK 4.89  0.0049 







Figure 6: Reverse phCE HPLC-MS/MS separation and identification of tryptic peptides (oxidized and non-oxidized) of HAS. Skyline 








Figure 7: (left) Reverse phase HPLC-MS/MS separation and identification of tryptic peptides (oxidized and non-oxidized) of HSA. Skyline generates a color for 
each peptide based on the peptide sequence and modifications. Peptide (AVM…) was selected for targeted proteomics due to its high intensity. (right) Spectral 
library of peptide (AVM…) identified by MASCOT algorithm. 
 
 
Figure 8: Intensity comparison of optimized MRM for the tryptic peptides   between 
smokers and     non-smokers. Three sequence specific fragment ions b9 (N- terminus 
protected fragment ions), y7, y9 (C-terminus protected fragment ions) were considered 




3.4.2 Larger amount of proteins is cleared in the urine of smokers compared to non-smokers 
     Intensities observed for the top 30 peptides representing proteins predominately exist in the 
collected samples indicate that more segments of an individual protein were detected in smokers 
(Fig. 9 a &b). The selected peptides in control group were mapped to 13 different proteins in 
which, seven peptides were derived from HSA. The intensity of the tryptic peptides ranged from 
4.6109 to 2.91010 for IGKC and AMBP proteins, respectively. On the other hand, 30 tryptic 
peptides selected for smokers represented seven proteins only, in which, 14 peptides were mapped 
to HSA. Intensities of the selected peptides extended from 1.051010 to 6.441010 for HSA and 
AMBP proteins, respectively. The increased number of covered peptides per protein in smokers 
suggests secretion of higher amount of proteins in smokers. The increased level of proteins in the 
renal clearance of the experimental group is reflected in the intensities gained for oxidized and 
reduced tryptic peptides of HSA (Fig 9c). In which, almost all Met containing domains show 
higher intensities of the oxidized peptides in smokers compared to control group except for the 
peptide MPCAEDYLSVVLNQLCVLHEK which is non-significantly regulated in the opposite. 
     The increased level of proteins cleared in the urine samples of smokers could be mainly 
attributed the increased level of MSO in smokers. Studies have established a well connection 
between oxidative stress and protein degradation. Lai et al. tested the mechanism of oxidation and 
degradation of proteins caused by particulate matter (PM) (tobacco smoke is known to cause fine 
PM that exceeds the limits of outdoor pollutants)  (64).   Other studies have shown increased level 
of certain proteins expression in smokers, e.g.  C-reactive protein, fibrinogen, interleukin-6 and 





































Figure 9: Higher level of plasma proteins is detected in the urine of smokers. (a) Top 30 abundant 
peptides match 13 proteins, of which 7 peptides were shown to represent HSA. (b) Top 30 
abundant peptides are shown to match 7 proteins in which almost 50% of the selected peptides 
match Met containing tryptic fragments of HSA. (c) Intensity of reduced vs. oxidized Met 
containing peptides of HSA (smokers and non-smokers). 



























3.4.3 Methionine sulfoxide formation by cigarette smoke is associated with the degradation 
of plasma proteins 
     Increased number of peptides show large, statistically significant changes in the intensity of 
peptides with oxidized Met residues in smokers compared to non-smokers. Gel band labeled HSA 
contains predominately intact serum albumin and the other regions of the gel contains a mixture 
of proteins including peptides derived from HSA. Comparison of MSO in peptides digested from 
intact HSA (table 3) shows an increase in the intensity of oxidized peptides in smokers relative to 
non-smokers, but these changes have low statistical significance. However, comparison of MSO 
in the peptides derived from the HSA fragments found in HSA in band labeled D revealed an 
increased level of oxidative modification (p-value 0.053). 
     There is a significant association between oxidation of serum proteins mainly caused by tobacco 
smoke and their fragmentation. Degradation of proteins has been extensively studied. One possible 
causation is perhaps the deleterious effects of ROS. Proteolysis of cigarette-smoke induced 
oxidized proteins can occur in several ways. Agarwal et al. assessed the fragmentation and 
oxidation in proteins excreted in urine of 20 males with chronic kidney disease using 
immunoblotting. Infusion of iron was used as a source of carbonylation. They found that 
degradation of HSA was directly proportional with the increased level of total protein excretion 
(67). Panda et al. described a two-step process for the degradation of cigarette smoke induced 
degradation including oxidation followed by a rapid proteolytic via the action of proteases (68). 
Smoking is also known to activate transcription factors, mainly of those with proteolytic activity. 
Pedersen et al. noticed elevated levels of  muscle-specific (MAFBx) factor that regulates ubiquitin-




of proteins caused by cigarette smoke that relies on releasing of microvesicles with proteolytic 
activities when they exposed human macrophage to tobacco smoke extract (70). 
 
3.5 CONCLUSIONS 
     Analysis of data revealed a comparable difference in protein intensities across all forty bio-
samples used in the current study. Group comparisons of MSO content between both smoker and 
control populations demonstrated statistically significant fold change in smokers. Furthermore, we 
noticed significant fold change of oxidized methionine residues in the lower mass region 
suggesting an association between oxidation of Met and protein turnover (p-value = 0.053). 
Analysis of total proteins also showed an increased level of proteins cleared in the urine samples 
of smokers irrespective of methionine oxidation. The current study is the first to address 
methionine sulfoxide proteome in human serum proteins. However. It is early to confirm that the 
majority of oxidation occurred in vivo. Further evaluation of sample processing is necessary to 
observe the extent to which oxidation was introduced during sample preparations.  
 



















Table 3: Group comparison of MSO in intact HSA found in HSA band between 24 smokers and 16 non-smokers showing significant 
fold changes and p-values for individual peptides as well as whole HSA. In the whole gel and nearly significant in D band, however, 














whole gel HSA band 




SHCIAEVENDEMPADLPSLAADFVESK 1.75 0.0328 0.84 0.7431 
SHCIAEVENDEMPADLPSLAADFVESKDVCK 1.8 0.0018 1.41 0.5827 
RMPCAEDYLSVVLNQLCVLHEK 2.32 0.0017 3.34 0.0729 
MPCAEDYLSVVLNQLCVLHEK 2.28 0.0017 2.37 0.1427 
MPCAEDYLSVVLNQLCVLHEKTPVSDR 1.73 0.0018 1.46 0.3941 
AVMDDFAAFVEK 1.25 0.3237 1.32 0.6324 
 
C band D band 




SHCIAEVENDEMPADLPSLAADFVESK 1.08 0.8703 2.85 0.1849 
SHCIAEVENDEMPADLPSLAADFVESKDVCK 1.68 0.5174 1.7 0.1849 
RMPCAEDYLSVVLNQLCVLHEK 1.22 0.8258 2.02 0.1849 
MPCAEDYLSVVLNQLCVLHEK 1.66 0.5174 2.91 0.1249 
MPCAEDYLSVVLNQLCVLHEKTPVSDR 1.75 0.5174 1.27 0.5009 
AVMDDFAAFVEK 0.79 0.8258 1.21 0.6796 
 
C & D bands 
ETYGEMADCCAK 2.27 0.1659 
0.0987 
SHCIAEVENDEMPADLPSLAADFVESK 1.66 0.2899 
SHCIAEVENDEMPADLPSLAADFVESKDVCK 1.65 0.1659 
RMPCAEDYLSVVLNQLCVLHEK 1.51 0.2899 
MPCAEDYLSVVLNQLCVLHEK 2.11 0.1659 
MPCAEDYLSVVLNQLCVLHEKTPVSDR 1.47 0.1659 
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3.7 SUPPORTING INFORMATION  
 




Protein Description Fold 
 Change 
P-Value 
P07911 Uromodulin OS=Homo sapiens GN=UMOD PE=1 SV=1 2.93 0 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 3.48 0 
Q92820 Gamma-glutamyl hydrolase OS=Homo sapiens GN=GGH PE=1 SV=2 2.01 0.0003 
Q7Z3Y9 Keratin, type I cytoskeletal 26 OS=Homo sapiens GN=KRT26 PE=1 SV=2 2.45 0.0003 
B3KVV6 cDNA FLJ41607, highly similar to Homo sapiens alpha-2-macroglobulin-like 1 (A2ML1) PE=2 SV=1 2.24 0.0003 
Q16610 Extracellular matrix protein 1 OS=Homo sapiens GN=ECM1 PE=1 SV=2 2.36 0.0004 
Q6P1J6 Phospholipase B1, membrane-associated OS=Homo sapiens GN=PLB1 PE=1 SV=3 2.11 0.0005 
P08571 Monocyte differentiation antigen CD14 OS=Homo sapiens GN=CD14 PE=1 SV=2 2.21 0.0006 
P68871 Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 2.07 0.0008 
P02790 Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 2.09 0.0014 
P12830 Cadherin-1 OS=Homo sapiens GN=CDH1 PE=1 SV=3 2.36 0.0017 
P05155 Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 1.71 0.0017 
P15309 Prostatic acid phosphatase OS=Homo sapiens GN=ACPP PE=1 SV=3 1.82 0.0026 
P11142 Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 2.52 0.003 
O43707 Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2 1.62 0.0037 
P30530 Tyrosine-protein kinase receptor UFO OS=Homo sapiens GN=AXL PE=1 SV=3 2.09 0.0037 
P19652 Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 1.93 0.0042 
P19835 Bile salt-activated lipase OS=Homo sapiens GN=CEL PE=1 SV=3 1.78 0.0042 
Q7Z3Y8 Keratin, type I cytoskeletal 27 OS=Homo sapiens GN=KRT27 PE=1 SV=2 1.88 0.0042 
P01617 Ig kappa chain V-II region TEW OS=Homo sapiens PE=1 SV=1 2.17 0.0042 
P01625 Ig kappa chain V-IV region Len OS=Homo sapiens PE=1 SV=2 2.13 0.0042 
O00560 Syntenin-1 OS=Homo sapiens GN=SDCBP PE=1 SV=1 1.96 0.0042 
Q9NS89 Alpha1A-voltage-dependent calcium channel (Fragment) OS=Homo sapiens GN=CACNA1A PE=2 SV=1 115.58 0.0042 
P05090 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 2.36 0.0055 








Protein Description Fold 
 Change 
P-Value 
Q03001 Dystonin OS=Homo sapiens GN=DST PE=1 SV=4 2.04 0.0055 
P09668 Pro-cathepsin H OS=Homo sapiens GN=CTSH PE=1 SV=4 2.09 0.0058 
Q9NQ84 G-protein coupled receptor family C group 5 member C OS=Homo sapiens GN=GPRC5C PE=1 SV=2 1.82 0.0075 
B4DPR2 cDNA FLJ50830, highly similar to Serum albumin OS=Homo sapiens PE=2 SV=1 1.84 0.0075 
P01011 Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 1.6 0.008 
P04745 Alpha-amylase 1 OS=Homo sapiens GN=AMY1A PE=1 SV=2 1.64 0.008 
P00450 Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 1.63 0.008 
P09211 Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 1.77 0.008 
P01023 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 1.66 0.0091 
P02768 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 1.96 0.0091 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 1.78 0.0094 
P19022 Cadherin-2 OS=Homo sapiens GN=CDH2 PE=1 SV=4 1.97 0.0094 
Q96PD5 N-acetylmuramoyl-L-alanine amidase OS=Homo sapiens GN=PGLYRP2 PE=1 SV=1 1.71 0.0094 
P0DMV8 Heat shock 70 kDa protein 1A OS=Homo sapiens GN=HSPA1A PE=1 SV=1 1.77 0.0098 
Q99698 Lysosomal-trafficking regulator OS=Homo sapiens GN=LYST PE=1 SV=3 1.79 0.0102 
C8C504 Beta-globin OS=Homo sapiens GN=HBB PE=3 SV=1 1.72 0.0108 
P29375 Lysine-specific demethylase 5A OS=Homo sapiens GN=KDM5A PE=1 SV=3 1.61 0.0119 
A8K2U0 Alpha-2-macroglobulin-like protein 1 OS=Homo sapiens GN=A2ML1 PE=1 SV=3 1.5 0.0126 
R4H484 X-DING-CD4 (Fragment) OS=Homo sapiens PE=2 SV=1 1.85 0.0126 
P01034 Cystatin-C OS=Homo sapiens GN=CST3 PE=1 SV=1 1.66 0.0132 
Q71DI3 Histone H3.2 OS=Homo sapiens GN=HIST2H3A PE=1 SV=3 1.69 0.0132 
Q5JSZ5 Protein PRRC2B OS=Homo sapiens GN=PRRC2B PE=1 SV=2 1.9 0.0132 
P16444 Dipeptidase 1 OS=Homo sapiens GN=DPEP1 PE=1 SV=3 1.75 0.0164 
O43451 Maltase-glucoamylase, intestinal OS=Homo sapiens GN=MGAM PE=1 SV=5 1.61 0.0164 
P17900 Ganglioside GM2 activator OS=Homo sapiens GN=GM2A PE=1 SV=4 1.81 0.0164 
L8E9E6 Alternative protein SOD1 OS=Homo sapiens GN=SOD1 PE=4 SV=1 1.64 0.0189 
P07339 Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 1.61 0.0205 
P02760 Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 1.81 0.0206 








Protein Description Fold 
 Change 
P-Value 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 1.67 0.0255 
P02751 Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 1.45 0.0261 
P05067 Amyloid beta A4 protein OS=Homo sapiens GN=APP PE=1 SV=3 1.73 0.0271 
P51654 Glypican-3 OS=Homo sapiens GN=GPC3 PE=1 SV=1 1.48 0.0279 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 1.5 0.0281 
P02042 Hemoglobin subunit delta OS=Homo sapiens GN=HBD PE=1 SV=2 1.63 0.0287 
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein OS=Homo sapiens GN=HSPG2 PE=1 
SV=4 
1.37 0.0307 
P02787 Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 1.46 0.0359 
P04264 Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 1.44 0.037 
P01859 Ig gamma-2 chain C region OS=Homo sapiens GN=IGHG2 PE=1 SV=2 1.59 0.0376 
P54107 Cysteine-rich secretory protein 1 OS=Homo sapiens GN=CRISP1 PE=1 SV=1 1.63 0.0393 
P98164 Low-density lipoprotein receptor-related protein 2 OS=Homo sapiens GN=LRP2 PE=1 SV=3 1.44 0.0405 
P05154 Plasma serine protease inhibitor OS=Homo sapiens GN=SERPINA5 PE=1 SV=3 1.48 0.0439 
P01009 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 1.42 0.0447 
P08473 Neprilysin OS=Homo sapiens GN=MME PE=1 SV=2 1.59 0.0447 
P15144 Aminopeptidase N OS=Homo sapiens GN=ANPEP PE=1 SV=4 1.47 0.0456 
Q9HC84 Mucin-5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 1.48 0.047 
E9PGN7 Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=1 1.54 0.047 




Table S2: Tryptic peptides identified with MSO in the current study 
 
Protein Acc# Gene Peptide Modified Sequence 
Q8WZ42 TTN DGGSPIKGYIVEM[+16]QEEGTTDWK 
P05067 APP AM[+16]ISR 
P68871 HBB FFESFGDLSTPDAVM[+16]GNPK 
O95336 PGLS FALGLSGGSLVSM[+16]LAR 
P01023 A2M VVSM[+16]DENFHPLNELIPLVYIQDPK 
A8K2U0 A2ML1 YSM[+16]VELQDPNSNR 
A8K2U0 A2ML1 YTYGKPM[+16]LGAVQVSVC[+57]QK 
A8K2U0 A2ML1 FQM[+16]EDLVYNPEQVPR 
A8K2U0 A2ML1 GSLVM[+16]EGQK 
A8K2U0 A2ML1 WM[+16]AGNQLPSGC[+57]YANVGNLLHTAMK 
A8K2U0 A2ML1 DVDDPM[+16]VSQGLR 
A8K2U0 A2ML1 YATTAYM[+16]PSEEINLVVK 
A8K2U0 A2ML1 M[+16]LSGFSPMEGTNQLLLQQPLVK 
P68032 ACTC1 DLTDYLM[+16]K 
P68032 ACTC1 LC[+57]YVALDFENEM[+16]ATAASSSSLEK 
P01011 SERPINA3 DLDSQTMM[+16]VLVNYIFFK 
P01011 SERPINA3 AKWEM[+16]PFDPQDTHQSR 
P01011 SERPINA3 WEM[+16]PFDPQDTHQSR 
P01011 SERPINA3 M[+16]EEVEAMLLPETLK 
P01011 SERPINA3 MEEVEAM[+16]LLPETLK 
P01011 SERPINA3 FNRPFLMIIVPTDTQNIFFM[+16]SK 
P12821 ACE SM[+16]YETPSLEQDLER 
P19652 ORM2 TLM[+16]FGSYLDDEKNWGLSFYADKPETTK 
P60709 ACTB TTGIVM[+16]DSGDGVTHTVPIYEGYALPHAILR 
P60709 ACTB DLYANTVLSGGTTM[+16]YPGIADR 
P01009 SERPINA1 LGM[+16]FNIQHC[+57]K 
P01009 SERPINA1 GTEAAGAM[+16]FLEAIPMSIPPEVK 
P01009 SERPINA1 GTEAAGAMFLEAIPM[+16]SIPPEVK 
P01009 SERPINA1 FNKPFVFLM[+16]IEQNTK 
O43707 ACTN4 TIQEM[+16]QQK 
O43707 ACTN4 ISIEM[+16]NGTLEDQLSHLK 
O43707 ACTN4 GISQEQM[+16]QEFR 
O43707 ACTN4 M[+16]APYQGPDAVPGALDYK 
P15144 ANPEP DSQYEM[+16]DSEFEGELADDLAGFYR 
P15144 ANPEP SEYM[+16]EGNVR 
P15144 ANPEP KVVATTQM[+16]QAADAR 
P15144 ANPEP VVATTQM[+16]QAADAR 
P15144 ANPEP DLTALSNM[+16]LPK 
P15144 ANPEP DLM[+16]VLNDVYR 






Gene Peptide Modified Sequence 
P15144 ANPEP M[+16]LSSFLSEDVFK 
P15144 ANPEP QYM[+16]PWEAALSSLSYFK 
P04745 AMY1A SGNEDEFRNM[+16]VTR 
P04745 AMY1A IYVDAVINHM[+16]C[+57]GNAVSAGTSSTC[+57]GSYFNPGSR 
P04745 AMY1A IAEYM[+16]NHLIDIGVAGFR 
P04745 AMY1A NWGEGWGFM[+16]PSDR 
P04745 AMY1A M[+16]AVGFMLAHPYGFTR 
P04745 AMY1A MAVGFM[+16]LAHPYGFTR 
Q9H2P0 ADNP SLPSQQM[+16]VNR 
Q12802 AKAP13 IMSGVYSQGM[+16]M[+16]ADLLFEQQM[+16]VEK 
P54802 NAGLU SFGM[+16]TPVLPAFAGHVPEAVTR 
P02768 ALB ETYGEM[+16]ADC[+57]C[+57]AK 
P02768 ALB SHC[+57]IAEVENDEM[+16]PADLPSLAADFVESK 
P02768 ALB SHC[+57]IAEVENDEM[+16]PADLPSLAADFVESKDVC[+57]K 
P02768 ALB RM[+16]PC[+57]AEDYLSVVLNQLC[+57]VLHEK 
P02768 ALB M[+16]PC[+57]AEDYLSVVLNQLC[+57]VLHEK 
P02768 ALB M[+16]PC[+57]AEDYLSVVLNQLC[+57]VLHEKTPVSDR 
P02768 ALB AVM[+16]DDFAAFVEK 
P05062 ALDOB GILAADESVGTM[+16]GNR 
P02760 AMBP M[+16]TVSTLVLGEGATEAEISMTSTR 
P02760 AMBP MTVSTLVLGEGATEAEISM[+16]TSTR 
P02760 AMBP M[+16]TVSTLVLGEGATEAEISM[+16]TSTR 
P02760 AMBP ETLLQDFRVVAQGVGIPEDSIFTM[+16]ADR 
P02760 AMBP VVAQGVGIPEDSIFTM[+16]ADR 
P02760 AMBP VVAQGVGIPEDSIFTM[+16]ADRGEC[+57]VPGEQEPEPILIPR 
P02760 AMBP KEDSC[+57]QLGYSAGPC[+57]M[+16]GMTSR 
P02760 AMBP KEDSC[+57]QLGYSAGPC[+57]MGM[+16]TSR 
P02760 AMBP EDSC[+57]QLGYSAGPC[+57]M[+16]GMTSR 
P02760 AMBP EDSC[+57]QLGYSAGPC[+57]MGM[+16]TSR 
P08519 LPA TPEYYPNAGLIM[+16]NYC[+57]R 
P63010 AP2B1 SQPDM[+16]AIM[+16]AVNSFVK 
P05090 APOD M[+16]TVTDQVNC[+57]PK 
Q01814 ATP2B2 TGTLTTNRM[+16]TVVQAYVGDVHYK 
P50895 BCAM LEVPVEMNPEGYM[+16]TSR 
O75882 ATRN IMQSSQSM[+16]SK 
P16278 GLB1 AGATLDLLVENM[+16]GR 
Q15878 CACNA1E AWIDKAEEVM[+16]LAEENK 
Q8N4F0 BPIFB2 HVGTEGSM[+16]ATVGLSQQLFDSALLLLQK 
P12830 CDH1 M[+16]ALEVGDYK 
P55290 CDH13 M[+16]TAFDADDPATDNALLR 






Gene Peptide Modified Sequence 
Q9BY67 CADM1 EGDALELTC[+57]EAIGKPQPVM[+16]VTWVR 
P07384 CAPN1 DM[+16]ETIGFAVYEVPPELVGQPAVHLK 
P31944 CASP14 EGSEEDLDALEHM[+16]FR 
P31944 CASP14 M[+16]AEAELVQEGK 
P07339 CTSD TM[+16]SEVGGSVEDLIAK 
P07339 CTSD FDGILGM[+16]AYPR 
P07339 CTSD ISVNNVLPVFDNLM[+16]QQK 
P07339 CTSD DPDAQPGGELM[+16]LGGTDSK 
P07339 CTSD AIGAVPLIQGEYM[+16]IPC[+57]EK 
P08185 SERPINA6 NIFISPVSISMALAM[+16]LSLGTC[+57]GHTR 
P08571 CD14 ITGTM[+16]PPLPLEATGLALSSLR 
P09668 CTSH GIM[+16]GEDTYPYQGK 
Q49A88 CCDC14 GPQNSNTRGM[+16]EEASAPGIISALSK 
P00450 CP M[+16]YSVNGYTFGSLPGLSMC[+57]AEDR 
P00450 CP M[+16]YYSAVDPTK 
P00450 CP M[+16]YYSAVDPTKDIFTGLIGPMK 
P00450 CP MYYSAVDPTKDIFTGLIGPM[+16]K 
P00450 CP M[+16]YYSAVDPTKDIFTGLIGPM[+16]K 
P00450 CP DIFTGLIGPM[+16]K 
P00450 CP M[+16]FTTAPDQVDKEDEDFQESNK 
P19835 CEL AM[+16]IAYWTNFAK 
P01024 C3 TVM[+16]VNIENPEGIPVK 
P01024 C3 YFKPGMPFDLM[+16]VFVTNPDGSPAYR 
P01024 C3 ILLQGTPVAQM[+16]TEDAVDAER 
P0C0L4 C4A LNM[+16]GITDLQGLR 
P0C0L4 C4A SM[+16]QGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLK 
Q12860 CNTN1 M[+16]NNGDVDLTSDR 
Q12860 CNTN1 ILALAPTFEM[+16]NPM[+16]K 
P10643 C7 M[+16]PYEC[+57]GPSLDVC[+57]AQDER 
P22792 CPN2 SLM[+16]LSYNAITHLPAGIFR 
P54107 CRISP1 M[+16]SWSEEAAQNAR 
P54107 CRISP1 YC[+57]DM[+16]TESNPLER 
P39059 COL15A1 SSQALAFESSAGIFM[+16]GNAGATGLER 
Q7Z3J2 C16orf62 AAISLVPEVPKM[+16]INIDGK 
P12109 COL6A1 FEPGQSYAGVVQYSHSQM[+16]QEHVSLR 
P01034 CST3 LVGGPM[+16]DASVEEEGVR 
P01034 CST3 ASNDM[+16]YHSR 
P01034 CST3 AFC[+57]SFQIYAVPWQGTM[+16]TLSK 
O60494 CUBN SPENPM[+16]QVSSTGNELAIR 
O60494 CUBN FISDGSGSGTGFQATFM[+16]K 






Gene Peptide Modified Sequence 
O60494 CUBN STGEYM[+16]FIR 
O60494 CUBN FC[+57]GTSLPSSQWSSGEVM[+16]YLR 
O60494 CUBN FESSM[+16]EEC[+57]GGDLQGSIGTFTSPNYPNPNPHGR 
O60494 CUBN RITLM[+16]FNNLR 
O60494 CUBN ITLM[+16]FNNLR 
O60494 CUBN VGDADGPLM[+16]WR 
O60494 CUBN M[+16]SFTYQIADC[+57]NR 
Q15828 CST6 AAQAAVASYNM[+16]GSNSIYYFR 
P01040 CSTA M[+16]IPGGLSEAKPATPEIQEIVDK 
Q07507 DPT AGM[+16]EWYQTC[+57]SNNGLVAGFQSR 
P24855 DNASE1 GAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVM[+16]LK 
P16444 DPEP1 DSPVIDGHNDLPWQLLDM[+16]FNNR 
Q03001 DST VEPQLAEDQPVHGDIDLVM[+16]NLIDNHK 
Q02413 DSG1 ALNSM[+16]GQDLERPLELR 
Q02413 DSG1 QEPSDSPM[+16]FIINR 
Q02413 DSG1 YVM[+16]GNNPADLLAVDSR 
Q02413 DSG1 EM[+16]QDLGGGER 
Q8WXX0 DNAH7 AM[+16]EKM[+16]ITEWDAVEFVIHSYR 
Q16610 ECM1 M[+16]GTTARAALVLTYLAVASAASEGGFTATGQR 
P01133 EGF HPTQHNLFAM[+16]SLFGDR 
P01133 EGF LC[+57]SDIDEC[+57]EM[+16]GVPVC[+57]PPASSK 
P08246 ELANE LGNGVQC[+57]LAM[+16]GWGLLGR 
P15311 EZR IAQDLEM[+16]YGINYFEIK 
Q12805 EFEMP1 TSSYLC[+57]QYQC[+57]VNEPGKFSC[+57]M[+16]C[+57]PQGYQVVR 
Q12805 EFEMP1 FSC[+57]M[+16]C[+57]PQGYQVVR 
Q12805 EFEMP1 C[+57]VC[+57]PVSNAM[+16]C[+57]R 
Q12805 EFEMP1 QTSPVSAM[+16]LVLVK 
P02751 FN1 VTIM[+16]WTPPESAVTGYR 
P02751 FN1 FTNIGPDTM[+16]R 
P02751 FN1 TEIDKPSQM[+16]QVTDVQDNSISVK 
P02751 FN1 EINLAPDSSSVVVSGLM[+16]VATK 
P15328 FOLR1 TELLNVC[+57]M[+16]NAK 
Q9ULV1 FZD4 INIPIGPC[+57]GGM[+16]C[+57]LSVK 
P06396 GSN VPFDAATLHTSTAM[+16]AAQHGM[+16]DDDGTGQK 
Q92820 GGH M[+16]FQNFPTELLLSLAVEPLTANFHK 
P15586 GNS SM[+16]C[+57]GYQTFFAGK 
P15586 GNS SNFEPFFMM[+16]IATPAPHSPWTAAPQYQK 
P15586 GNS LM[+16]MLQSC[+57]SGPTC[+57]R 
P51654 GPC3 IYDM[+16]ENVLLGLFSTIHDSIQYVQK 
Q9NZH0 GPRC5B M[+16]RETAFEEDVQLPR 






Gene Peptide Modified Sequence 
P28799 GRN C[+57]DM[+16]EVSC[+57]PDGYTC[+57]C[+57]R 
Q9NQ84 GPRC5C SSPEQSYQGDM[+16]YPTR 
Q9NQ84 GPRC5C AFSM[+16]DEPVAAK 
P09211 GSTP1 DQQEAALVDM[+16]VNDGVEDLR 
P68431 HIST1H3A FQSSAVM[+16]ALQEAC[+57]EAYLVGLFEDTNLC[+57]AIHAK 
Q71DI3 HIST2H3A FQSSAVM[+16]ALQEASEAYLVGLFEDTNLC[+57]AIHAK 
P02042 HBD FFESFGDLSSPDAVM[+16]GNPK 
P69905 HBA1 M[+16]FLSFPTTK 
P69905 HBA1 VADALTNAVAHVDDM[+16]PNALSALSDLHAHK 
P02790 HPX DYFM[+16]PC[+57]PGR 
P00738 HP YVM[+16]LPVADQDQC[+57]IR 
P00738 HP SPVGVQPILNEHTFC[+57]AGM[+16]SK 
P0DMV8 HSPA1A SINPDEAVAYGAAVQAAILM[+16]GDK 
P11142 HSPA8 NQVAM[+16]NPTNTVFDAK 
P11142 HSPA8 RFDDAVVQSDM[+16]K 
P01860 IGHG3 DTLM[+16]ISR 
P30740 SERPINB1 IPELLASGMVDNM[+16]TK 
P30740 SERPINB1 VLELPYQGEELSM[+16]VILLPDDIEDESTGLK 
P30740 SERPINB1 ADLSGM[+16]SGAR 
P05155 SERPING1 KVETNM[+16]AFSPFSIASLLTQVLLGAGENTK 
P05155 SERPING1 VETNM[+16]AFSPFSIASLLTQVLLGAGENTK 
P05155 SERPING1 VPM[+16]MNSK 
P05155 SERPING1 LEDM[+16]EQALSPSVFK 
P05155 SERPING1 VTTSQDM[+16]LSIMEK 
P05155 SERPING1 FPVFM[+16]GR 
Q12794 HYAL1 ALYPSIYM[+16]PAVLEGTGK 
Q16270 IGFBP7 GYC[+57]APGM[+16]EC[+57]VK 
P01859 IGHG2 TTPPM[+16]LDSDGSFFLYSK 
P05154 SERPINA5 ALASAAPSQSIFFSPVSISM[+16]SLAMLSLGAGSSTK 
P05154 SERPINA5 ALASAAPSQSIFFSPVSISMSLAM[+16]LSLGAGSSTK 
P05154 SERPINA5 ALASAAPSQSIFFSPVSISM[+16]SLAM[+16]LSLGAGSSTK 
P05154 SERPINA5 M[+16]QILEGLGLNLQK 
P05154 SERPINA5 DGFQLSLGNALFTDLVVDLQDTFVSAM[+16]K 
P05154 SERPINA5 TLYLADTFPTNFRDSAGAM[+16]K 
P05154 SERPINA5 NLDSNAVVIM[+16]VNYIFFK 
P05154 SERPINA5 M[+16]QQVENGLSEK 
Q7Z3Y9 KRT26 VTM[+16]QNLNDR 
P35908 KRT2 DVDNAYM[+16]IK 
P35908 KRT2 VLYDAEISQIHQSVTDTNVILSM[+16]DNSR 
P35908 KRT2 DYQELM[+16]NVK 






Gene Peptide Modified Sequence 
P13645 KRT10 NHEEEM[+16]KDLR 
P13645 KRT10 NVSTGDVNVEM[+16]NAAPGVDLTQLLNNMR 
P13645 KRT10 NVSTGDVNVEMNAAPGVDLTQLLNNM[+16]R 
P13645 KRT10 NVSTGDVNVEM[+16]NAAPGVDLTQLLNNM[+16]R 
P02533 KRT14 GQVGGDVNVEM[+16]DAAPGVDLSR 
Q7Z3Y8 KRT27 VTM[+16]QNLNDRLASYLENVR 
Q99456 KRT12 TDLEM[+16]QIESLNEELAYMK 
P13646 KRT13 TLQGLEIELQSQLSM[+16]K 
P08779 KRT16 GQTGGDVNVEM[+16]DAAPGVDLSR 
P19013 KRT4 VLYDAELSQMQTHVSDTSVVLSM[+16]DNNR 
P13647 KRT5 NM[+16]QDLVEDFK 
P13647 KRT5 DVDAAYM[+16]NK 
P13647 KRT5 EYQELM[+16]NTK 
P02538 KRT6A GM[+16]QDLVEDFK 
P35527 KRT9 STM[+16]QELNSR 
P35527 KRT9 M[+16]TLDDFR 
P35527 KRT9 QVLDNLTM[+16]EK 
P35527 KRT9 SDLEM[+16]QYETLQEELMALK 
P35527 KRT9 SDLEMQYETLQEELM[+16]ALK 
P35527 KRT9 SDLEM[+16]QYETLQEELM[+16]ALK 
P35527 KRT9 SDLEM[+16]QYETLQEELMALKK 
P35527 KRT9 SDLEMQYETLQEELM[+16]ALKK 
P35527 KRT9 SDLEM[+16]QYETLQEELM[+16]ALKK 
P35527 KRT9 TLNDM[+16]RQEYEQLIAK 
P04264 KRT1 NM[+16]QDMVEDYR 
P04264 KRT1 NMQDM[+16]VEDYR 
P04264 KRT1 KDVDGAYM[+16]TK 
P04264 KRT1 DVDGAYM[+16]TK 
P04264 KRT1 LDNLQQEIDFLTALYQAELSQM[+16]QTQISETNVILSM[+16]DNNR 
P04264 KRT1 DYQELM[+16]NTK 
P04264 KRT1 M[+16]SGEC[+57]APNVSVSVSTSHTTISGGGSR 
P29375 KDM5A ILYPYELFQSGVSLM[+16]GVQM[+16]PNLDLKEK 
P07288 KLK3 FLRPGDDSSHDLM[+16]LLR 
P07288 KLK3 VM[+16]DLPTQEPALGTTC[+57]YASGWGSIEPEEFLTPK 
P07288 KLK3 FM[+16]LC[+57]AGR 
Q9UKR3 KLK13 M[+16]WPLALVIASLTLALSGGVSQESSK 
P01596  DIQM[+16]TQSPSTLSASVGDR 
P01600  DIQM[+16]TQSPSSLSASVGDR 
O95835 LATS1 VGLSQDAQDQM[+16]RK 
P01611  DIQM[+16]TQSPSSVSASVGDR 






Gene Peptide Modified Sequence 
P01042 KNG1 IYPTVNC[+57]QPLGM[+16]ISLMK 
P01042 KNG1 IYPTVNC[+57]QPLGMISLM[+16]K 
P06870 KLK1 QADEDYSHDLM[+16]LLR 
P06870 KLK1 VTDFM[+16]LC[+57]VGHLEGGK 
P01617  DIVM[+16]TQSPLSLPVTPGEPASISC[+57]R 
P01613  DIQM[+16]TQSPSSLSATVGDR 
P01625  DIVM[+16]TQSPDSLAVSLGER 
Q08380 LGALS3BP AAFGQGSGPIM[+16]LDEVQC[+57]TGTEASLADC[+57]K 
Q12907 LMAN2 LPTGYYFGASAGTGDLSDNHDIISM[+16]K 
Q12907 LMAN2 LFQLM[+16]VEHTPDEESIDWTK 
Q9NZU5 LMCD1 QLM[+16]HQLPIYDQDPSR 
P61626 LYZ LGM[+16]DGYR 
P10253 GAA LDVM[+16]METENR 
P10253 GAA LDVMM[+16]ETENR 
P10253 GAA AHFPLDVQWNDLDYM[+16]DSR 
P10253 GAA DGFRDFPAM[+16]VQELHQGGR 
P10253 GAA DFPAM[+16]VQELHQGGR 
P10253 GAA YM[+16]MIVDPAISSSGPAGSYRPYDEGLR 
P10253 GAA YM[+16]M[+16]IVDPAISSSGPAGSYRPYDEGLR 
P10253 GAA WTQLGAFYPFM[+16]R 
P10253 GAA NHNSLLSLPQEPYSFSEPAQQAM[+16]R 
P98164 LRP2 IDM[+16]VNLDGSYR 
P98164 LRP2 AFM[+16]DGSNRK 
P98164 LRP2 LGWPAGVTLDM[+16]ISK 
P98164 LRP2 VC[+57]GC[+57]PYGM[+16]R 
P98164 LRP2 DNDC[+57]GDM[+16]SDEKDC[+57]PTQPFR 
P98164 LRP2 TC[+57]EDIDEC[+57]DILGSC[+57]SQHC[+57]YNM[+16]R 
P98164 LRP2 IASANM[+16]DGTSVK 
P98164 LRP2 TVM[+16]SLDYDSVSDR 
P98164 LRP2 ANKYDGSGQIAM[+16]TTNLLSQPR 
P98164 LRP2 YDGSGQIAM[+16]TTNLLSQPR 
P98164 LRP2 TC[+57]VDIDEC[+57]TEM[+16]PFVC[+57]SQK 
Q99698 LYST SLMSPGFMVISPSGFTASPYEGENSSNIIPQQM[+16]AAHM[+16]LR 
Q7Z7M0 MEGF8 GAM[+16]YLLGGLTAGGVTR 
Q2M2H8 MGAM2 WM[+16]QLGAFYPFSR 
O43451 MGAM YEYGTLDNM[+16]R 
O43451 MGAM VM[+16]AYVPDAVWYDYETGSQVR 
Q9H8L6 MMRN2 TPVC[+57]TTGQGSGSTATVFAM[+16]AELQK 
Q9H8L6 MMRN2 SLSGTAFGGFLM[+16]FK 
P42345 MTOR NLLPSNDPVVM[+16]EM[+16]ASKAIGR 






Gene Peptide Modified Sequence 
Q9HC84 MUC5B AAQLPDM[+16]PLEELGQQVDC[+57]DR 
Q9HC84 MUC5B M[+16]C[+57]FNYEIR 
Q6W4X9 MUC6 FHGTC[+57]TYILLQSPQLPEDGALM[+16]AVYDK 
Q6W4X9 MUC6 ETDPC[+57]SM[+16]SQLNK 
Q6W4X9 MUC6 LSC[+57]PQRPQM[+16]FLASC[+57]QAPK 
Q6W4X9 MUC6 FGAAC[+57]APTC[+57]QM[+16]LATGVAC[+57]VPTK 
O00533 CHL1 VM[+16]TPAVYAPYDVK 
P20929 NEB SLQDDPKLVLSM[+16]NVAK 
P08473 MME LIQNM[+16]DATTEPC[+57]TDFFK 
P08473 MME FIM[+16]DLVSSLSR 
P61916 NPC2 AVVHGILM[+16]GVPVPFPIPEPDGC[+57]K 
Q6UX06 OLFM4 ITYGQGSGTAVYNNNM[+16]YVNM[+16]YNTGNIAR 
Q9UN73 PCDHA6 GHPPM[+16]AGHC[+57]TVLVRILDK 
Q92824 PCSK5 VSHLYGFGLMDAEAMVM[+16]EAEK 
P05164 MPO NQINALTSFVDASM[+16]VYGSEEPLAR 
P05164 MPO FWWENEGVFSM[+16]QQR 
Q6P1J6 PLB1 QDWTERPQQVC[+57]MGVM[+16]TVLSDIIR 
P14923 JUP ALM[+16]GSPQLVAAVVR 
P13797 PLS3 M[+16]INLSVPDTIDER 
P98160 HSPG2 EHLLM[+16]ALAGIDTLLIR 
Q96PD5 PGLYRP2 SPPTM[+16]VDSLLAVTLAGNLGLTFLR 
P08F94 PKHD1 EDTVVGEDM[+16]R 
P15309 ACPP SPIDTFPTDPIKESSWPQGFGQLTQLGM[+16]EQHYELGEYIR 
P15309 ACPP ESSWPQGFGQLTQLGM[+16]EQHYELGEYIR 
P15309 ACPP SRLQGGVLVNEILNHM[+16]K 
P15309 ACPP LQGGVLVNEILNHM[+16]K 
P15309 ACPP LQGGVLVNEILNHM[+16]KR 
P15309 ACPP FAELVGPVIPQDWSTEC[+57]M[+16]TTNSHQGTEDSTD 
Q5JSZ5 PRRC2B AGEQGEAM[+16]K 
P07737 PFN1 DSLLQDGEFSM[+16]DLR 
P41222 PTGDS AALSM[+16]C[+57]K 
P41222 PTGDS TM[+16]LLQPAGSLGSYSYR 
P41222 PTGDS M[+16]ATLYSR 
P15151 PVR VQLTGEPVPM[+16]AR 
Q5JT25 RAB41 NLNVM[+16]FIETSAKTGYNVK 
Q16769 QPCT QIAEGTSISEM[+16]WQNDLQPLLIER 
Q16769 QPCT M[+16]ASTPHPPGAR 
Q16769 QPCT GVPVLHLIPSPFPEVWHTM[+16]DDNEENLDESTIDNLNK 
P02753 RBP4 FSGTWYAM[+16]AK 
P02753 RBP4 LLNNWDVC[+57]ADM[+16]VGTFTDTEDPAK 






Gene Peptide Modified Sequence 
P07998 RNASE1 QHM[+16]DSDSSPSSSSTYC[+57]NQMMR 
P07998 RNASE1 QHMDSDSSPSSSSTYC[+57]NQMM[+16]R 
Q8WZ75 ROBO4 M[+16]SC[+57]QASGQPPPTIR 
P07602 PSAP GEM[+16]SRPGEVC[+57]SALNLC[+57]ESLQK 
P07602 PSAP LGPGM[+16]ADIC[+57]K 
P07602 PSAP NYISQYSEIAIQM[+16]MMHMQPK 
P07602 PSAP NYISQYSEIAIQMMMHM[+16]QPK 
P07602 PSAP NYISQYSEIAIQMMM[+16]HM[+16]QPK 
P17900 GM2A IPC[+57]TDYIGSC[+57]TFEHFC[+57]DVLDM[+16]LIPTGEPC[+57]PEPLR 
Q8WVN6 SECTM1 DSHAGLYM[+16]WHLVGHQR 
O00560 SDCBP LYPELSQYM[+16]GLSLNEEEIR 
P29508 SERPINB3 ENNIFYSPISITSALGM[+16]VLLGAK 
P29508 SERPINB3 GKDLSM[+16]IVLLPNEIDGLQK 
P29508 SERPINB3 DLSM[+16]IVLLPNEIDGLQK 
P29508 SERPINB3 LM[+16]EWTSLQNMR 
P29508 SERPINB3 LMEWTSLQNM[+16]R 
P29508 SERPINB3 TMGMVDIFNGDADLSGM[+16]TGSR 
Q96P63 SERPINB12 NIFFSPLSLSAALGM[+16]VR 
Q9UIV8 SERPINB13 ADYSGM[+16]SSGSGLYAQK 
Q96PV0 SYNGAP1 DFLSDM[+16]AM[+16]SEVDR 
Q8WXH0 SYNE2 KTEAELEM[+16]LK 
P22105 TNXB TITTM[+16]IDGPQDLR 
P02787 TF SM[+16]GGKEDLIWELLNQAQEHFGK 
P02787 TF M[+16]YLGYEYVTAIR 
P02787 TF IM[+16]NGEADAMSLDGGFVYIAGK 
P02787 TF IMNGEADAM[+16]SLDGGFVYIAGK 
P02787 TF IM[+16]NGEADAM[+16]SLDGGFVYIAGK 
P02787 TF TAGWNIPM[+16]GLLYNK 
P02787 TF LC[+57]M[+16]GSGLNLC[+57]EPNNK 
P02787 TF LC[+57]M[+16]GSGLNLC[+57]EPNNKEGYYGYTGAFR 
P02788 LTF GEADAM[+16]SLDGGYVYTAGK 
Q9Y4A5 TRRAP ELSEKDIGNQLHM[+16]LTNR 
P30530 AXL LAYQGQDTPEVLM[+16]DIGLR 
P07911 UMOD M[+16]AETC[+57]VPVLR 
P07911 UMOD LEC[+57]GANDM[+16]K 
P07911 UMOD LEC[+57]GANDM[+16]KVSLGK 
P07911 UMOD SLGFDKVFM[+16]YLSDSR 
P07911 UMOD VFM[+16]YLSDSR 
P07911 UMOD INFAC[+57]SYPLDM[+16]K 
P07911 UMOD INFAC[+57]SYPLDM[+16]KVSLK 






Gene Peptide Modified Sequence 
P07911 UMOD VGGTGM[+16]FTVR 
P02774 GC VM[+16]DKYTFELSR 
Q14508 WFDC2 DQC[+57]QVDSQC[+57]PGQM[+16]K 
Q6ZQQ6 WDR87 EM[+16]AQAEGKFAQK 
Q5THJ4 VPS13D EKDDLSPQPLM[+16]TDFER 
E9PFZ2 CP M[+16]YYSAVEPTKDIFTGLIGPMK 
Q53ET8  ELNVM[+16]FIETSAKAGYNVK 
Q53FJ5  M[+16]VTDIQTAVR 
E9PGN7 SERPING1 VTTSQDMLSIM[+16]EK 
Q6MZV7 DKFZp686C11235 EPQVYTLPPSREEM[+16]TK 
B3KVV6  NSATSTTNLYTQALLAYIFSLAGEM[+16]DIR 
C8C504 HBB FFKSFGDLSTPDAVM[+16]GNPK 
Q9UL83  EIVM[+16]TQSPATLSVSPGER 
Q9NS89 CACNA1A EHM[+16]AHRQGSSSVSGSPAPSTSGTSTSR 
Q4W4Y1 DRIP4 M[+16]VPVSVQQSLAAYNQR 
E7ER45 MGAM YTLLPYLYTLM[+16]QK 
M0QY60 ZNF714 M[+16]NVM[+16]LENYK 
F6KPG5  SHC[+57]IAEVENDEM[+16]RADLPSLAADFVESK 
L8E9E6 SOD1 GMLETWAM[+16] 
A2JA16  DIQM[+16]TQSPSSLPASVGDR 
B4DPR2  SHC[+57]IAEVENDGM[+16]PADLPSLAADFVESK 
R4H484  ITYM[+16]SPDYAAPTLAGLDDATK 
A0SEH4 CCKBR M[+16]LLVI 























4. CONCLUSIONS AND FUTURE STUDIES 
     Blood plasma is a powerful material used in discovering biomarkers of human physiological 
changes. However, the elevated concentration of plasma proteins often limits the study of blood 
biomarkers. Alternatively, the ease, noninvasive procedure of collecting urine samples, and as a 
result of being a filtrate of plasma enabled this biofluid to become a powerful tool substituting 
plasma in biomarker studies for a wide array of diseases. MS-based methods to profile urine with 
increasing depth in identifying thousands of fragments including unique peptides enables detecting 
of polypeptides with high accuracy and degree of confidence.  
     Oxidative posttranslational modification of proteins is known to impact the structure and 
consequently the function of these biomolecules. Increasing number of studies have examined the 
role of a variety of PTMs in signal transductions or the deleterious effects of these modifications 
might have on human physiology. The impact of oxidative stress on side chain residues especially 
those with sulfur group in the structure including methionine has been underpinned by several 
research groups.  
     As it was anticipated, analysis of data revealed a noticable variation in protein intensities across 
all forty bio-samples used in the current study, mainly because of the complexity of urine texture. 
Group comparisons of methionine sulfoxide content between both smoker and control populations 
demonstrated statistically significant fold change in smokers. Furthermore, we noticed 
significantly higher levels of oxidized methionine residues in the lower mass region, suggesting 
an association between oxidation of Met and protein turnover (p-value = 0.053). Analysis of total 




irrespective of methionine oxidation. The current study is the first to address and provide a 
quantitative measurement of methionine sulfoxide proteome in human serum proteins, and in 
evaluating the impact of cigarette smoking on plasma proteome. However. It is necessary to 
quantitatively evaluate the extent of oxidation that might be introduced during sample 
preparations. Moreover, integrating strategies to evaluate the level of antioxidants especially those 
directly linked to oxidation of methionine including methionine sulfoxide reductases (MsrA and 
MsrB) provide additional sights to the changes observed in the analysis of data since the two 
variables are interchangeably involved in the whole process of oxidative stress and in activating 
transcription of genes responsible in generating a wide spectrum of other antioxidants. 
 
